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Articular cartilage can easily become damaged or diseased and it does not 
have the ability to heal itself.  A tissue engineering approach to regenerate cartilage is 
to integrate chondrocytes, the primary cell in cartilage, with biomaterials and 
biomolecules.  Currently, there is limited knowledge on how all these factors 
influence the expression of upstream insulin-like growth factor-1 (IGF-1) signaling 
molecules.  In an effort to better understand how IGF-1 and phenotypic, type II 
collagen, expression can be modified by altering construct properties, chondrocytes 
were embedded in alginate hydrogels.  Increasing alginate concentration resulted in 
an upregulation of IGF-1 expression and by increasing cell density further enhanced 
IGF-1 expression.  Additional changes in chondrocyte signaling were observed when 
exogenously delivering IGF-1 to the constructs.  IGF-1 expression decreased while 
the receptor for IGF-1 (IGF-1R) expression as well as type II collagen increased in 
the presence of excess IGF-1 indicating that it has a key role in IGF-1 and 
  
chondrocyte interaction.  An extracellular matrix molecule, such as hyaluronic acid 
(HA), provides anchorage sites for chondrocytes and therefore the influence of HA on 
IGF-1 signaling was also investigated.  The incorporation of HA created a dual affect 
by entrapping exogenously delivered IGF-1 as well as directly interacting with 
chondrocytes.  As a result, the IGF-1 expression levels varied depending on HA 
concentration and there was also a lack of correlation with IGF-1R expression.  The 
upregulated expression of type I collagen, a fibroblastic marker, by chondrocytes 
indicated that HA can overcome the beneficial affects of IGF-1.  These in vitro works 
were also compared to an in vivo study.  Alginate/HA constructs with embedded 
chondrocytes were pre-cultured with IGF-1 and then subcutaneously implanted into 
mice.  Similar levels of type II collagen were observed for the constructs.  However, 
by increasing the HA content a decrease in IGF-1 synthesis occurred with an increase 
in type I collagen staining.  Pre-incubating the samples with IGF-1 led to a further 
decrease in IGF-1 production but was able to reverse the affects of HA on type I 
collagen expression.  This research demonstrates that construct properties can alter 
endogenous IGF-1 signaling and overall shows the importance of understanding these 
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Articular cartilage is located on the surface of articulating joints, such as those 
found in the knees.  Damage of articular cartilage due to trauma and degenerative 
osteoarthritis often results in permanent injuries.  This condition is partially due to the 
lack of vasculature in the tissue, which limits the ability for cartilage to properly heal.  To 
date, the options for clinical treatment such as arthroscopic lavage, autografting, and 
allografting provide temporary relief but do not result in complete regeneration of 
cartilage.  These inadequacies have prompted tissue engineers to seek other methods for 
repairing articular cartilage. To accomplish this task, tissue engineers must be able to 
harmoniously integrate the three major components of healthy tissues: cells, soluble 
growth factors and physical matrices for cellular support. 
Chondrocytes are the primary cell type in articular cartilage.  These cells express 
type II collagen, a phenotypic extracellular matrix marker, and insulin-like growth-factor 
(IGF-1), a soluble growth factor shown to increase cartilage matrix synthesis. 
Chondrocytes can be embedded in a degradable hydrogel to create an implantable tissue 
engineered construct.  Currently, there is limited knowledge on how biomaterial 
properties affect chondrocyte expression of IGF-1 signaling molecules. Therefore, this 
research is focused on endogenous IGF-1 signaling by chondrocytes embedded in 
hydrogels. 
Bio-polymers are commonly used as cellular scaffolds because it can provide 
temporary support for chondrocytes to grow cartilage.  By using degradable polymers, 
newly formed tissue can eventually replace the graft to leave behind naturally developed 




similarity in water retention to cartilage.  Additionally, in hydrogels chondrocytes are 
able to maintain their rounded morphology, which has been linked to increased type II 
collagen expression.  Chondrocytes are known to remain viable in polymer hydrogels but 
interestingly material properties on chondrocyte signaling have been minimally studied.  
Alginate hydrogels were chosen as the biomaterial because it has minimal interaction 
with chondrocytes due to its lack of amine groups.  As a result, individual components 
can be altered and chondrocytes signaling can be closely monitored in a 3-D 
environment.  Preliminary studies indicate that chondrocytes within alginate hydrogels 
express IGF-1, while retaining type II collagen expression.  Therefore, for this research 
we proposed the following objectives: 
 
(1) Investigate the effect of alginate concentration and cell density on 
chondrocyte IGF-1 and type II collagen expression; 
(2) Investigate the effect of exogenous IGF-1 concentration on 
endogenous IGF-1, IGF-1 receptor (IGF-1R), and IGF-1 binding 
protein-3 (IGFBP-3) expression as well chondrocyte phenotypic 
stability; 
(3) Investigate the effect of hyaluronic acid content on IGF-1 delivery and 
endogenous IGF-1, IGF-1R, and IGFBP-3 expression as well as type II 
collagen and type I collagen expression; 
(4) Investigate in vivo the effect of exogenous delivery of IGF-1 and 
hyaluronic acid concentration on glycosaminoglycan, IGF-1, type II 





Overall, this research will undertake the completion of these objectives to provide 
a novel approach to regenerate articular cartilage defects, specifically focusing on 
monitoring the expression of upstream IGF-1 signaling molecules by chondrocytes 
embedded within alginate hydrogels.  By closely understanding how chondrocyte 
expressions can be controlled by construct properties, this will help improve the tissue 




2 Background – Engineering Articular Cartilage 
2.1 Articular Cartilage and Chondrocyte Signaling* 
2.1.1 Introduction 
The proper functionality of healthy tissue requires maintenance.  Even after tissue 
has undergone trauma, it attempts to repair itself.  However, there are tissues within the 
body that are unable to completely regenerate when inflicted with severe stress, such as 
articular cartilage.  The field of tissue engineering can alleviate this problem by providing 
cells, biological molecules and scaffolding materials to facilitate regeneration of healthy 
tissue. In order to achieve this task, fundamental mechanisms of cartilage tissue function 
needs to be understood.  Cartilage is composed of components, such as cells, proteins and 
macromolecules, which all play a role in maintaining the well-being of the tissue.  There 
has been considerable evidence that the interaction of chondrocytes with proteins and 
extracellular matrix play an important role in the homeostasis of cartilage.  This is a 
continuously evolving area of study as biologists are furiously discovering new details of 
the cellular signaling pathways involved in the communication of chondrocytes.  Recent 
studies have implicated that alterations in the signaling pathways of chondrocytes can 
lead to osteoarthritis, a degenerative condition of articular cartilage.  We propose that the 
success of tissue engineers involves understanding the intricacy of chondrocytes 
signaling mechanisms in order to maintain their proper function while in contact with 
biomaterial scaffolds.  To this end, we first investigate the basic biology of articular 
cartilage.  Then we will examine the activation of signaling pathways that occur by 
________________________________________________________________________ 
 
* This chapter was published as: Yoon DM and Fisher JP. Chondrocyte Signaling and Artificial Matrices 




chondrocytes due to the interaction with proteins (growth factors and cytokines) and 
extracellular matrix components (type II collagen, glycosaminoglycans and 
proteoglycans), which are listed in Table 2.1. Finally, we discuss the effects polymers of 
synthetic biomaterials. 
 
Table 2.1.  Abbreviations for proteins involved in chondrocyte signaling. 
 
ACTR activin receptor 
ALK activin-like receptor 
AP1 activating protein 1 
BMP bone morphogenic protein 
c-met hepatocyte growth factor receptor 
COX2 cyclooxygenase-2 
DAN differential screening-selected gene aberrative in neuroblastoma 
ECM extracellular matrix 
EGF epithelial growth factor 
ERK extracellular signal-regulated kinase 
FADD fas-activated death domain protein 
FAK focal adhesion kinase 
FGF fibroblastic growth factor 
FGFR fibroblastic growth factor receptor 
Flt-1 fms-like tyrosine kinase 
GAG glycosaminoglycan 
Grb2 growth factor receptor-binding protein 2 
IGF insulin-like growth factor 
IGF-1R insulin-like growth factor-1 receptor 
IGFBP insulin-like growth factor binding protein 
IKK inhibitor of NF-κB kinase 
IL interleukin 
IL-1ra interleukin-1 receptor antagonist 
IL-1RacP interleukin-1 receptor associated protein 
IL-R interleukin receptor 
IRAK interleukin-1 receptor activate kinase 
IRS insulin receptor substrate 
I-κB inhibitor of kappa B 
JNK c-Jun N-terminal protein kinase 
KDR kinase insert domain-containing receptor 
MAPK mitogen-activated protein kinase 
MEK mitogen-activated protein kinase kinase 
MH2 mad homology 2 
MMP metallanoproteases 
MyD88 adaptor protein 




NIK NF-κB-inducing kinase 
NRP-1 neutropilin-1 
PDGF platelet-derived growth factor 
PDK phosphatidylinositol 3-kinase-dependent kinases 
PGE2 prostaglandin E2 
PI3K phosphatidylinositol 3-kinase 
PKC protein kinase C 
Ras rat sarcoma guanine triphosphatase 
SH2 src homology 2 
Shc src homology 2 domain containing transforming protein 1 
SOS son-of-sevenless 
Sox9 sex-determining region Y-related gene 
Src sarcoma 
STAT signal transducer and activator of transcription 
TACE tumor necrosis factor-converting enzyme 
TGF transforming growth factor 
TNF tumor necrosis factor 
TNF-R tumor necrosis factor receptor 
TRADD tumor necrosis factor receptor-associated death domain protein 
TRAF tumor necrosis factor receptor-associated factor 
VEGF vascular endothelial growth factor 
 
 
2.1.2 Biology of Articular Cartilage 
 
Articular cartilage is an avascular, alymphatic tissue that is predominately found 
on the surface of articulating joints [1, 2].  Its function is to provide protection and enable 
articulation of subchondral bone, allowing the joint to undergo compressive forces as 
well as smooth movement [3, 4].  This functionality may be attributed to the zonal 
architectural composition of articular cartilage, which is composed of extracellular matrix 
(ECM) components and chondrocytes.  There are four subsections of articular cartilage 
known as the superficial, middle, deep and calcified zones [1, 4-6]. 
The main ECM components in articular cartilage are collagen, 
glycosaminoglycans (GAGs) and proteoglycans.  Structural integrity of articular cartilage 




collagen found in articular cartilage is type II collagen, which provides an interconnected 
network of support through the mobile restriction of GAGs and proteoglycans [2, 4, 6-8]. 
Articular cartilage has two main types of GAGs: chondroitin sulfate and keratin sulfate 
[2, 9].  Proteoglycans are large protein core molecules that have numerous amounts of 
GAGs attached to it, comprising up to 95% of their composition [9].  Aggrecan and 
hyaluronic acid are the most prevalent proteoglycans in articular cartilage and are 
partially responsible for maintaining the integrity of articular cartilage under compressive 
forces [6, 9, 10].  Other smaller proteoglycans in articular cartilage include decorin, 
biglycan and perlecan [1, 2, 5, 11].  Glycosaminoglycans and proteoglycans are both 
negatively charged, allowing for continuous hydration of the tissue [4].  Thus, the water 
content in articular cartilage can comprise about 75% of the total weight [2, 4, 12].  This 
high water content, as well as a lack of vascularization of articular cartilage necessitates 
diffusion the leading mechanism for nutrient and waste exchange between chondrocytes 
and the synovial fluid. 
The extracellular matrix is the structural component of articular cartilage that 
provides a framework for cell viability and function. Chondrocytes, which are the 
primary cell in articular cartilage, comprise only 5% of cartilage volume [2, 4, 13].  They 
have a unique physical appearance in that they maintain a spherical morphology.  
Chondrocytes also provide the necessary homeostasis for healthy articular cartilage by 
communicating with both the ECM and soluble proteins within and surrounding the 
tissue [4].  These interactions are controlled by protein receptors, which are located 
within the plasma membrane of chondrocytes.  Each receptor has specific affinity for 




Like most tissue, articular cartilage can become diseased or damaged.  One of the 
most common articular cartilage diseases is known as osteoarthritis.  In this state, 
articular cartilage is more fibrous and contain higher levels of type I collagen and type X 
collagen versus type II collagen [8, 12, 14, 15].  Additionally, the appearance of 
chondrocytes seems to be more fibroblastic in shape rather than spherical [14].  In order 
to repair osteoarthritic cartilage it is vital to understand how chondrocytes maintain the 
balance of growth factors necessary to create a healthy extracellular matrix.  Finally, it is 
critical to understand how chondrocytes interact with the extracellular matrix itself. 
2.1.3 Basic Principles of Cellular Signaling 
 
The functions of chondrocytes are stimulated during their attachment to the 
extracellular matrix or specifically when an extracellular signaling molecule binds to a 
receptor.  These extracellular interactions start a cascade of steps that eventually leads to 
cellular effects of the cytoskeleton, gene expression, and metabolism.  A general outline 
of a signal cascade starts with an extracellular signal that attaches to a receptor protein 
within the plasma membrane of the cell [16-18].  Cell surface receptors are proteins 
located within the plasma membrane.  Their basic structure contains an amino terminus, 
transmembrane domain, and carboxyl tail.  The attachment of extracellular signaling 
molecules to the amino terminus of the receptor results in the release or activation of 
intracellular signaling molecules by the cytoplasmic side of the receptor [19].  The 
intracellular signaling molecules then interact with target proteins to further relay its 
signal. There are multitudes of signaling pathways that can lead to either results in the 




another [16].  Additionally, there are a variety of regulatory proteins present in the areas 
such as the extracellular matrix and cytoplasm of the cell. 
2.1.4 Native Effectors on Chondrocyte Signaling 
2.1.4.1 Extracellular Matrix 
The structural integrity and properties of articular cartilage is partially due to the 
extracellular matrix. Chondrocytes are responsible to maintain compounds in the ECM, 
such as type II collagen and aggrecan. Conversely, chondrocytes need the ECM to 
function. This is mediated by integrin receptors within the cell membrane of 
chondrocytes that become activated when bound to the ECM [10, 11, 21-23].  
Additionally, integrin signaling can affect growth factor and cytokine receptors [22, 24]. 
Integrins are glycoproteins that contain α and β subunits that have an influence in 
signal transduction and cell shape [18, 25, 26].  The response of the integrin is controlled 
by both the extracellular and cytoplasmic domains.  However, the β subunits interact with 
cytoskeletal proteins to activate various signaling cascades (Figure 2.1).  Signaling 
through integrins depends on the formation of focal adhesions, where cytoskeletal and 
other proteins are concentrated at the surface of the plasma membrane.  Aggregation of 
these focal adhesions activates the FAK and Shc pathways.  Intracellular activation of 
FAK involves its phosphorylation by β subunit of the integrin.  This activation allows 
FAK to attach to the Src homology 2 (SH2) domains of the Src proteins [22].  FAK has 
been found to affect the JNK, MAPK, p38 and PI3K pathways [22].  The activation of 
the Shc pathway is initiated by the phosphorylation of the Shc protein when in contact 




Grb2 and SOS proteins that eventually attach to a Ras protein, responsible for activating 
























Figure 2.1.  Integrin signaling pathway of chondrocytes. Integrins interact with ECM 
proteins to phosphorylate Shc and/or FAK proteins. These molecules lead to the 
activation of the MAPK, PI3K, p38, and/or JNK pathways. 
 
 
The most predominant integrin expressed by chondrocytes is the α5β1, which is 
known to be a fibronectin receptor [24, 25, 27, 28].  However, α5β1 has also been found 
to interact with type II collagen [27].  Other integrins that interact with type II collagen 
are α1β1, α2β1, and α10β1 [24, 28].  β1 integrins have a vital role in the relationship of 
chondrocytes to the ECM and have been identified in cartilage [11, 23, 28, 29].  
Chondrocyte attachment to type II collagen through integrins α1β1, α2β1, and α3β1 has 
recently been identified and is critical to chondrocyte survival [24, 27, 30].  Others have 
stated that α1 and β3 integrins are not expressed by chondrocytes and α2 expression is 
low in the presence of type II collagen [23].  Another well known integrin receptor is  
CD44, which interacts with hyaluronan and has been found to be highly expressed in 




phosphorylation levels of FAK and ERK 1/2 protein compared to when the cells were in 
suspension.[24]  When chondrocytes are in contact with insulin-like growth factor-1 
protein and type II collagen, the production of the Shc, Grb2 and ERK 1/2 proteins 
increased.[31]  However, the presence of these respective proteins was less apparent 
when chondrocytes were attached to type I collagen surfaces in the presence of IGF-1.  
These results indicate that there is an interactive merging of integrins and growth factor 
signaling pathways. 
2.1.5 Signaling Molecules of Chondrocytes 
 
An initiator for cellular signaling is an extracellular signaling molecule, allowing 
cells to communicate amongst each other.  There are several different signaling 
transportation mechanisms: autocrine, paracrine, and endocrine.  A cell that releases 
signaling molecules that bind to receptors from the same cell is known autocrine 
signaling.  When a signal acts as a local mediator to neighboring cells it is referred to as 
paracrine signaling.  Finally, endocrine signaling involves ligands being distributed 
throughout the body.  Extracellular signaling molecules function is mediated by its 
binding to its receptor within the plasma membrane of the cell.  However, the 
extracellular signaling molecules are inhibited by antagonists, binding proteins that block 
the signaling protein’s ability to bind a cell surface receptor.  Most ligands have 
extracellular antagonists that can inhibit their function.  A balance must exist between the 
signal concentration, antagonist concentration, and their affinities for one another.  
Additionally, extracellular signaling molecules can become degraded by enzymes as well 




Chondrocytes synthesize and express various proteins referred to as growth 
factors, which affect their function.  The two main types of growth factors are anabolic 
and catabolic.  Anabolic growth factors enable chondrocytes to produce the necessary 
proteins to maintain its environment.  Catabolic growth factors do the opposite in that 
they degrade molecules within the extracellular matrix.  The interplay between these two 
types of growth factors is necessary in order to maintain homeostasis for articular 
cartilage through the initiation of appropriate signaling pathways. 
 
2.1.5.1 Growth Factors 
 
Insulin-like Growth Factor-1 
 
In articular cartilage, insulin-like growth factor-1 (IGF-1) is a dominant growth 
factor that leads to type II collagen, hyaluronan and aggrecan synthesis [2, 14, 32-35].  
Additionally, IGF-2 has also been found to affect the proteoglycan synthesis [36].  
Insulin-like growth factor is a protein that has similar homology to insulin [37].  More 
specifically, IGF-1 is a small soluble protein with a molecular weight of 7.5 kDa [38-40].  
Normal versus reparative cartilage show a lower response to IGF [41].  In the 
extracellular part of chondrocytes, IGF-1 is bound to an antagonist that maintains its 
stability.  There are 6 known IGF binding proteins (IGFBP) in cartilage, which can bind 
to extracellular matrix proteins [34, 42, 43].  The most predominant is IGFBP-3, which 
has a high affinity for IGF-1.[39, 40, 43, 44] IGFBP-3 has been found in both normal and 
osteoarthritic cartilage [36, 45].  However, its degradation is more apparent in cartilage 
that is damaged. It has been found that IGFBP-3 has a higher affinity for IGF-1 than its 
receptor, IGF-1R.  These binding proteins regulate the availability of the IGF-1. In order 




43].  IGF-1R is a heterodimeric protein, containing two α and two β subunits that are 
attached by disulfide bonds [37, 39, 40]. 
The binding of IGF-1 to the α subunits activates the β subunits to initiate several 
intracellular signaling pathways (See Figure 2.2) [39, 40].  The tyrosine kinases of insulin 
receptor substrates (IRS) can become activated as well as Shc proteins by 
phosphorylation.  Insulin receptor substrates lead to the activation of PI3K and MAPK 
pathways by binding to Grb2/SOS proteins.  When the Ras attaches to a Raf protein this 
initiates the MEK1/2 and then ERK1/2.  Both IRS and Shc lead to the same pathway. 
Besides the MAPK pathway it can go through the JNK and p38 pathway.  Conversely, 
IGF-1 has been observed not to activate JNK or p38 proteins [46].  For the PI3K 
pathway, the p85 and p110 subunits of PI3 kinase activate PDK1 and PDK2 to move and 
phosphorylate an Akt protein located within the membrane.  By activation of the PI3K 
pathway by IGF-1, chondrocyte have been found to express type II collagen and 
proteoglycans [39, 40].  Additionally, this has shown to inhibit nitric oxide production, 
which is stimulated through the p38, ERK1/2 and PKC pathways [39, 40].  The inhibition 








































Figure 2.2.  Signaling cascade of IGF-1. IGF-1 growth factors activate the β subunits of 
IGF-1R, which translocates proteins to the integrin to active the MAPK, PI3K, p38, 
and/or JNK pathway. 
 
 
Transforming Growth Factor-β Superfamily 
 
There are several ligands within the class of the transforming growth factor-β 
(TGF-β) superfamily.  In chondrocytes, the two major types are TGF-β1 and bone 
morphogenic proteins (BMPs).  Both of these ligands interact with two receptors, type I 
and type II, which are both required to transduce an intracellular signaling response [47].  
When a ligand adheres to the dimeric type II receptor, it causes the formation of a 
heterotetrameric complex with the dimeric type I receptor.  The activation of the type I 
receptor through phosphorylation of its serine/threonine kinase domains in the 
intracellular domain initiates the signaling cascade [48].  Since the type II receptor is 


























Figure 2.3.  Scheme of the TGF-β superfamily activation pathway. Type I and II 
receptors integrate together after the adherence to TGF-β proteins. This results in the 
phosphorylation of R-Smads. I-Smads act as intracellular antagonists to regulate the 
Smad signaling pathway. Co-Smads aid in the translocation of R-Smads into the nucleus, 
which affects chondrocyte gene expression. 
 
 
Most commonly in this pathway, the first intracellular proteins involved are Smad 
proteins.  There are three types of Smad proteins, which are referred to as regulator 
Smads (R-Smads), common Smads (Co-Smads) and inhibitory Smads (I-Smads).[49-52]  
All Smads except for I-Smads contain two important domains, an amino terminal (MH1) 
and carboxyl terminal (MH2), which have been found to be inactive when linked. I-
Smads have been found not to contain MH1 domains.  When R-Smads become 
phosphorylated by type II receptors, the interaction between MH1 and MH2 domains is 
terminated.  This enables the MH2 domains of R-Smads to interact with Co-Smads, 
whose role is to aid in transporting this complex to the nucleus and affect gene 
transcription [47].  I-Smads regulate and inhibit the activation of R-Smads by adhering to 
type I receptors. In general I-Smads have a higher affinity for type I receptors than R-




cytoplasm of chondrocytes is the proteolytic degradation of Smads. There is also 
competition between the TGF-β and BMP signaling pathway for R-Smads (e.g., Smad-4), 
as they share a common pathway [53, 54]. 
 
Transforming Growth Factor- β1 
 
Transforming growth factor-β1 (TGF-β1) is a protein that is part of the TGF-β 
superfamily that stimulates ECM synthesis [47, 53-56].  TGF-β1 has been found to affect 
the production and prevent degradation of proteoglycans in cartilage. More specifically, 
TGF-β1 increases aggrecan mRNA expression [14, 57].  A higher level of total 
proteoglycan synthesis was observed in the presence of type II collagen and TGF-β1 [14, 
57].  The stability and activation of TGF-β1 is regulated by the extracellular matrix, with 
a strong affinity for proteoglycan decorin [10, 58]. 
Three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3, are present in cartilage. 
However, the most prominent form in chondrocytes is TGF-β1, which is a 100 kDa 
peptide that contains two subunits, active (25 kDa) and inactive (75 kDa) [15, 59-61].  In 
order for TGF-β1 to bind to its receptor, TGF-βI (ALK5) or TGF-βII (ALK1), TGF-β1 
must first remove the inactive peptide [48, 49]. 
The specific Smad proteins that are part of the TGF-β1 pathway are Smad-2, -3, -
4, -6 and -7 [48, 50].  The two R-Smad proteins are Smad-2 and -3. The Co-Smad protein 
is Smad-4.  Finally, Smad-6 and -7 are considered I-Smads, which prevent complex 
formation of  R-Smads to Co-Smads [48, 49].  The amino terminal of Smad-7 has been 
found to affect the MH2 domain of R-Smads to inhibit TGF-β1 signaling [47].  The TGF-
β1 signaling pathway includes Smad, ERK, JNK and p38 kinases as well as the 




transport of R-Smads and their Co-Smads into the nucleus.  This is true for both TGF-β1 
and BMP [54]. 
It has been shown that tumor necrosis-α, a cytokine, prevents the activation of the 
TGF-β signaling through Smad-7, which can be produced by NF-κB [62].  Another 
cytokine, IL-1 has been found to increases the degradation of proteoglycans within 
articular cartilage.  When TGF-β1 was introduced to cartilage, it was found to overwhelm 
the tissue and prevent the effects of IL-1 [56].  This could be a result of Smad-7, which is 
responsible for inducing other signaling pathways, such as IL-1 [54].  The expression of 
aggrecan has been found to occur when Smad-2 is phosphorylated by TGF-β.  By 
expressing Smad-7 at high levels, it has been found to prevent the effects of TGF-β1 on 
the proteoglycan synthesis [55].  The intracellular signaling proteins Smad-2 and Smad-3 
both became phosphorylated when human chondrocytes are stimulated by TGF-β1, type 
II collagen, or both simultaneously [63].  Thus, indicating the possible influence of the 
integrin and TGF-β signaling pathways with each other. 
 
Bone Morphogenic Protein-7 
 
Bone morphogenic proteins (BMP), also referred to as osteogenic proteins (OP), 
are part of the TGF-β superfamily. BMPs are dimeric proteins that are approximately 32-
36 kDa. Several BMPs have been found to affect chondrocyte function, including BMP-
2, -4, -6 and -7 [12, 51, 64, 65].  However, the most notable effects have been found with 
BMP-7 [13].  Initially, BMPs are synthesized with an amino terminal region. The 
removal of this region allows BMPs to become activated.  When BMPs bind to type I and 
type II receptors (e.g., BMPR-IA, BMPR-IB, ACTR-I, BMPRII, ACTRII and ACTR-




between type I and type II receptors lead to the initiation of R-Smads (Smad-1, -5 or -8) 
[50, 51, 55].  The Co-Smad (Smad-4) aids in the translocation of the R-Smads to the 
nucleus allowing for gene transcription to occur. 
The BMP signaling pathway can be controlled both in the extracellular and 
intracellular part of the cell.  A few extracellular antagonists for BMP are noggin, 
chordin, follistan, and DAN [66].  BMP-2, -4 and -7 bind to noggin and chordin with a 
higher affinity than to BMP receptors [48, 50, 51, 66, 67].  DAN has been found to bind 
to BMP-2 [50].  The interaction of BMPs to their binding proteins can be broken down 
by BMP-1, a metalloprotease [51, 66].  Additionally, BMPs can adhere to extracellular 
matrix components such as collagen and heparin derivatives to prevent receptor 
activation [11, 66].  Soluble inhibitory intracellular proteins are present in chondrocytes, 
commonly referred to as Smad-6 and -7.  They both reside in the nucleus and travel into 
the cytoplasm after R-Smad activation. I-Smads adhere to the type I receptor and prevent 
the receptor interaction with the appropriate R-Smads.  There are a few regulatory 
elements in the BMP Smad signaling pathway.  For instance, Smad-6 can form a complex 
with Smad-1, therefore, preventing Smad-4 from binding. 
Several BMPs have been found to affect chondrocytic production of type II 
collagen, such as BMP-2, -4, -6 and -7 [12].  BMP-2 has been shown to promote the 
expression of type II collagen, aggrecan and not type X collagen [13, 15].  However, it 
does cause matrix degradation as well as induce the formation of proteases [13, 68].  
BMP-7 was found to maintain type II collagen and produce extracellular matrix 
components [13, 15, 69-71].  In comparison to basal medium, chondrocytes incubated 




sulfate [71].  Additionally, when chondrocytes were induced with BMP-7 an increase in 
the expression of the intracellular protein FAK, as well as other focal adhesion proteins, 
occurred [70].  In the presence of IL-1, BMP-7 allowed chondrocytes to maintain and 
continue synthesizing proteoglycans [15]. 
 
Platelet-Derived Growth Factor 
 
Platelet-derived growth factor (PDGF) is a 30 kDa glycoprotein found at platelet 
migration sites, such as injured tissue [12].  PDGF is a disulfide-linked heterodimer with 
four types of isoforms (PDGF-A, -B, -C and –D) [72].  There are two receptors for PDGF 
(-α, -β), which are both tyrosine kinase enzymes.  Individually, the two receptors have 
specificity for the different PDGF isoforms. PDGF- α and PDGF-β can also bind 
together, which results in an increase in enzymatic activity compared to when they are 
alone [72, 73].  The MAPK, PI3K and PKC signaling pathways have been found to 
become activated by PDGF in various cell lines [72].  PDGF has been shown to be 
produced locally in cartilage by chondrocytes [12, 15, 73].  PDGF can induce 
proteoglycan synthesis and aggrecan without inducing chondrocyte proliferation [15, 74, 
75].  By inducing chondrocytes with PDGF, an increase in IL-1 receptor gene expression 
was observed [75].  When PDGF and IL-1 were incubated together, there was noticeably 
more proteoglycan and aggrecan degradation.  This also correlated with an increase in 
mRNA of proteases, such as metalloproteases.  However, the extracellular matrix was 








Fibroblastic Growth Factor 
 
Fibroblast growth factor (FGF) is a polypeptide that is 14-16 kDa in molecular 
weight that binds to heparin proteoglycans, present in articular cartilage [11, 12].  It is 
known to be in a basic and acidic form.  FGF regulation of chondrocyte function is 
important to articular cartilage homeostasis by aiding in the synthesis and degradation of 
proteoglycans and type II collagen [76].  FGF determines its functionality as either an 
anabolic or catabolic growth factor by its concentration within articular cartilage.  The 
interaction of FGF with chondrocytes and its effect on the signaling pathway is still 
trying to be understood. It has been found that FGF-18, a specific type of fibroblastic 
growth factor, attaches to the FGF receptor-3 (FGFR-3).  The activation of the FGFR-3 
increased the gene expression of α1 integrin, which has been found to adhere to type II 
collagen.  Additionally, when FGF and IL-1 are exogenously added to chondrocytes, the 
expression of the IL-1 receptor increases, leading to an increase in matrix degradation 
attributed to IL-1 [77]. 
 
Epithelial Growth Factor, Vascular Endothelial Growth Factor, Hepatocyte 
Growth Factor 
 
Endothelial growth factor (EGF) is a very small protein, approximately 
1.6kDa.[12] It has been found to degenerate articular cartilage by breaking down 
proteoglycans.  The expression of type II collagen and aggrecan decreases in the presence 
of EGF [12, 78].  Some inflammatory responses that occur due to EGF have been a 
higher expression of cyclooxygenase-2 (COX2) and production of prostaglandin E2 
(PGE2) [79].  EGF has been found to activate the ERK 1/2 pathway but not effect Sox9, 




correlation between EGF and these inflammatory proteins can be seen by the activation 
of two pathways, primarily the ERK 1/2 and p38 kinase pathway [79]. 
Vascular endothelial growth factor (VEGF) is 23kDa protein, commonly 
associated with angiogenic activity [12, 80].  Several different isoforms of VEGF 
(VEGF121, VEGF165 and VEGR189) that have been found in normal and osteoarthritic 
cartilage [80, 81].  These VEGF proteins adhere to two different types of receptors, 
VEGF-R1 (Flt-1, fms-like tyrosine kinase) and VEGF-RII (KDR, kinase insert domain-
containing receptor).  Additionally, the co-receptor neutropilin-1 (NRP-1) increases the 
ability of VEGF to bind to VEGF-R2 [80, 82].  This co-receptor is activated in 
osteoarthritic cartilage at higher amounts compared to healthy cartilage [80].  VEGF has 
been found to adhere to heparin and heparin-sulfate proteoglycans.  Additionally, the 
adhesion of VEGF to the ECM can loosen the binding of basic FGF [82].  VEGF receptor 
gene expression is present in osteoarthritic cartilage with an increase in metalloproteases 
synthesis, specifically MMP1 and MMP3 [80].  When chondrocytes are induced with IL-
1β, VEGF protein synthesis decreases. However, VEGF production increases when 
chondrocytes are incubated with both IL-1β and TGF-β [83]. 
Hepatocyte growth factor (HGF) is a heterodimeric glycoprotein with an α and β 
subunit with molecular weights of 69kDa and 32 kDa respectively [84].  It has been 
found to bind collagen, chondroitin sulfate and hyaluronic acid.  When chondrocytes are 
introduced to HGF, there is an increase in proteoglycan synthesis compared to basal 
levels.  HGF attaches to a transmembrane receptor, c-met, which is a tyrosine kinase.  
The mRNA for HGF and c-met have both been observed in normal and arthritic cartilage.  




[15, 84].  This correlates to other data, indicating that HGF expression increased in the 
presence of IL-1 [15]. 
 




Interleukins (ILs) are cytokines present in articular cartilage that have been 
associated with degenerative cartilage.  There are many different forms of interleukins 
(IL-1, -4, -6, -8, -10, -11,-17 and -18) [12, 46, 85].  IL-1β has been found to strongly 
associate with damaged cartilage, increasing the expression of metallanoproteases and 
decreasing the expression of ECM components, such as type II collagen and aggrecan 
[12, 21, 70, 84, 86-88].  IL-1β is synthesized with two components to maintain it at an 
inactive state at a molecular weight of 31kDa [46].  An enzyme breaks down the IL-1β 
protein into a smaller active 17kDa fragment [21, 46]. 
There are two antagonists that control the extracellular IL-1s (Figure 2.4).  The 
interleukin-1 receptor I (IL-1RI) can attach to IL-1ra to inhibit signal transduction.  
Additionally, interleukin-1 receptor II (IL-1RII) binds to IL-1β [21, 35].  When IL-1β 
attaches to IL-1RI, an intracellular protein is recruited and becomes attaches to the 
receptor. This protein is known as the IL-1 associating protein (IL-1RAcP).  This enables 
an adaptor protein, MyD88, to procure kinases IRAK-1 and -2 to activate further 
intracellular proteins.  IRAK-1 and -2 stimulate the response of the NF-κB inducing 
kinase (NIK) to activate the IKKαβ complex, which finally induces the NF-κB protein to 
effect gene transcription.  Other signaling pathways that can become activated by IL-1 
are the MAPK and PI3K pathway [21, 46, 89].  It has been found that IL-1 activates the 




interleukins, such as IL-6, activate the JAK/STAT pathway [89, 90].  IL-6 as well as IL-1 
negatively affects the mRNA and protein amounts of Sox9, a protein that has been 
























Figure 2.4.  The transduction of the IL-1 pathway by chondrocytes. IL-1 can be bound to 
the IGF-1RII antagonist, which is present within the plasma membrane and in soluble 
form. Additionally, IL-1ra prevents IL-1 from adhering to its respective receptor, IL-1RI. 




In order for ILs to have an effect on gene expression by chondrocytes, they adhere 
to their respective receptors (IL-1R).  Low levels of ILs are maintained in healthy 
cartilage.  Additionally, this lessens the extent of MMPs production as well as its gene 
expression [46].  However, the presence of TGF-β, osteoarthritic cartilage was found to 
increase the expression of IL-6 [46, 85].  Additionally, IL-1β was found to increase the 
expression of TGF-β.  When chondrocytes are incubated with exogenous IGF-1, there is 
upregulation of IL-1RII [35]. 
Other forms of IL have shown to effect chondrocytes function. In the presence of 




well as produce nitric oxide, which causes apoptosis [21, 46, 91].  Therefore, decreasing 
the normal levels of proteoglycan synthesis.  In arthritic cartilage, the mRNA of IL-6 and 
-8 have been found to be present more often than healthy cartilage [46, 86].  The mRNA 
of several ILs show a trend of higher expression in damaged versus healthy cartilage, 
such as IL-6, IL-8 and IL-18 [86].  Chondrocytes expression of IL-18 increases in the 
presence of IL-1β.  When IL-1β and IL-18 are incubated with chondrocytes together, the 
results indicate that nitric oxide is produced concurrently with a decrease in proteoglycan 
synthesis [92]. 
 
Tumor Necrosis Factor-α 
 
Tumor necrosis factor-α (TNF-α) is another cytokine that acts similarly to ILs on 
chondrocytes [93].  TNF-α has been found to increase gene expression of MMPs and 
decrease the expression of extracellular matrix components [12, 78, 93].  TNF-α gene 
expression and their respective receptors are more present in damaged cartilage compared 
to normal cartilage [86, 94].  It has an initial molecular weight of 51 kDa and reduces 
down to 17 kDa [12, 95].  It is synthesized as a membrane bound protein, but after it is 
cleaved off the membrane by a metalloproteinase known as TACE, it becomes activated 
and can adhere to its appropriate receptor, TNF-R1 or TNF-R2 [94-96].  This enables the 
receptors to attach to either two cytoplasmic proteins, TRAF2/5 and FADD, through an 
adaptor protein, TRADD (TNF-R1 associated death domain protein) [95, 96].  The TRAF 
protein activates two main signaling pathways, MAPK and NF-κB. The MAPK signaling 
pathway includes transcriptional factors such as AP1 [96].  It has been recently 
discovered that chondrocytes activate the MEK pathways with minimal detection of the 




initiated by the TRAF protein.  NF-κB can be further controlled by I-κB proteins through 
the IKK complex, which is also recruited by TRAF proteins [95, 96].  Through the 
activation of the NF-κB signaling pathway, TNF-α, similar to IL-1β, affects type II 
collagen expression [78, 93]. 
Chondrocytes incubated with exogenous TNF-α resulted in the expression of IL-6 
[85].  The synthesis of IGFBPs by chondrocytes was shown to be greater in the presence 
of TNF-α, which could limit the availability of IGF-1 [98].  Other studies have shown 
that chondrocytes induced with EGF and TNF-α affects the mRNA of type II collagen 
and aggrecan more significantly compared to their individual effects [78, 93]. 
2.1.6 Tissue Engineering Approaches to Regulate Signaling 
 
The interactions of environmental cues and chondrocytes have been proven to be 
important in determining cell function. In the field of tissue engineering, it is vital to fully 
understand these underlying principles to create an appropriate biomaterial scaffold that 
can integrate and eventually heal the tissue.  Therefore, many researchers have looked 
into biomaterials.  Both natural and synthetic polymers have been utilized to aid in 
chondrocyte encapsulation.  Natural polymers are typically polysaccharides or 
polypeptide chains isolated from natural plants or organisms.  While synthetic polymers 
are fabricated and their properties can be altered more readily compared to natural 
polymers.  These polymers can be shaped into various three dimensional forms, such as 
meshes, foams and gels.  However, a common form that mimics the articular cartilage 
environment is a hydrogel.  The primary reason for interest in hydrogels as artifical 
matrices for chondrocytes is that they are water-laden polymer networks that have the 




encapsulation of chondrocytes as well as proteins within the bulk of the network.  
Hydrogels have been shown to maintain the spherical morphology and gene expression of 
chondrocytes [102]. 
Alginate is common natural polymer that has been used to encapsulate 
chondrocytes.  A unique property of alginate is that there is limited cellular adhesion due 
to the lack of cellular recognition proteins.  It has been found that chondrocytes 
encapsulated in alginate are able to express their phenotypic type II collagen expression 
[103-105].  Adult human chondrocytes were found to express aggrecan, 
metalloproteinases-3 and -8 for as long as eight months after their encapsulation in 
alginate beads [106].  The expression of BMP-2 was also apparent for chondrocytes in 
alginate [105].  A recent study has shown that when chondrocytes in alginate were 
incubated with exogenous IGF-1, there was an activation of both the PI3K and MAPK 
pathway, as demonstrated by phosphorylation of the Akt and ERK proteins respectively 
[107].  Inhibitors of Akt promoted a decrease in proteoglycan synthesis at a greater extent 
than compared to MEK inhibitors.  Thus, indicating the importance in the PI3K pathway 
with production of extracellular matrix components.  The effects of catabolic growth 
factor, IL-1β activated ERK, p38 and JNK proteins, but not Akt proteins [107]. 
Arginine-glycine-aspartic acid (RGD) sequences, which are commonly found in 
the ECM, have been covalently bound to alginate, forming a natural and synthetic hybrid.  
These constructs have allowed chondrocytes to express type II collagen at a far greater 
extent than when cultured in unmodified alginate [104].  Alternatively, cyclic RGD 
incubated with chondrocytes inside alginate decreased proteoglycan synthesis [23].  This 




Alginate gels that were embedded with fibrin gels allowed chondrocytic production of 
type II collagen, and proteoglycans, such as aggrecan [108, 109].  Alginate and type II 
collagen constructs promoted an increase in chondroitin-6 sulfate production by 
chondrocyte [110]  When stimulated with TGF-β1, an increase in keratin sulfate 
synthesis by chondrocytes was observed but also a decrease in the expression of 
chondroitin-6-sulfate was noted [57, 110].  The expression of type II collagen of 
chondrocytes within alginate beads was negatively effected by IL-1 while TGF-β1 and 
BMP-2 individually showed an enhancement [13, 105, 106].  BMP-2 also showed an 
greater aggrecan expression of chondrocytes in alginate [105].  When cultured in 
alginate, BMP-7 was found to effect the synthesis of type II collagen and proteoglycans 
greater than with just serum [111]. 
In terms of integrin expression, chondrocytes encapsulated in type II collagen and 
alginate were found to express α5β1 [23].  When these chondrocytes were incubated with 
an antibody that attached to β1 integrins with exogenous TGF-β1 there was a significant 
decrease in proteoglycan synthesis [23].  However, there was no effect when β1 integrins 
were blocked without TGF-β1.  This indicates that there is a possible interaction of TGF-
β1 to integrin signaling activation.  Further studies also show the effects of integrin 
signaling on chondrocytes.  When fibronectin beads are in contact with chondrocytes, the 
activation of the α5β1 integrin occurs [112].  This resulted in the phosphorylation of focal 
adhesion kinases, indicating the role of integrin signaling.  A higher level of proteoglycan 
synthesis is observed when FGF and IGF-1 are incubated with chondrocytes and 





Hyaluronic acid is a component in the extracellular matrix and therefore has been 
of interest for tissue engineers to encapsulate chondrocytes.  For instance, TGF-β mRNA 
expression increased when chondrocytes adhered to hyaluronic acid through the CD44 
integrin [10].  A modification of hyaluronic acid has been made with benzyl alcohol. In 
these constructs, chondrocytes expression of type II collagen and Sox9 increased while 
maintaining their low level of type I collagen expression and high level of aggrecan 
[113].  Hyaluronic acid has also been incorporated with other types of polymers, 
including alginate.  Chondrocytes are able to produce type II collagen and proteoglycans 
in both alginate beads and sponges that contain hyaluronic acid.  Investigations 
additionally indicated that the ECM protein levels were stabilized in the alginate beads 
versus alginate sponge structures [114]. 
Synthetic scaffolds have also been researched in determining the effect of 
chondrocyte signaling.  On poly(glycolic acid) meshes, it was found that chondrocytes 
produce type II collagen [8].  Further studies have been done with chondrocytes on a 
poly(glycolic acid) scaffold with incorporation of various growth factors [33].  IGF-1 
increased the GAG fraction compared to constructs with low protein supplemented 
media. TGF-β resulted in high type II collagen expression.  IL-4 prevented a decrease in 
GAG compared to other growth factors and PDGF was found to decrease GAG 
concentration.  Chondrocytes were encapsulated in photopolymerized poly(ethylene 
oxide) hydrogels with TGF-β1 and IGF-1 growth factors within poly(lactic-glycolic) acid 
microspheres [115].  There was an increase in the glycosaminoglycans concentrations 
with IGF-1 individually and with a combination of IGF-1 and TGF-β1.  Poly(ethylene 




poly(propylene fumarate-co-ethylene glycol) was shown to maintain the viability of 
chondrocytes encapsulated within this construct [116].  Proteoglycan synthesis occurred 
in these constructs, but was found to be lower when compared to alginate and agarose 
hydrogels by producing 25% of type II collagen. Recently, different armed-poly(ethylene 
glycol) polymers have been altered with metallanoprotease sensitive peptides [117].  This 
polymeric construct encapsulated chondrocytes and showed that the mRNA expression 
for type II collagen and aggrecan was highest for the poly(ethylene glycol) polymers that 
contained the MMP sensitive peptides versus without. Additionally, in these scaffolds, 
the expression of MMP-13 was the lowest compared to the scaffolds without MMP 
sensitive peptides. 
The effect of biomaterials on chondrocyte function is vital for creating a proper 
scaffolding environment to recreate articular cartilage.  It is important to investigate the 
effect of biomaterial properties on controlling molecular signaling of chondrocytes and 
therefore chondrocyte function.  We propose that fully understanding the interactions of 
chondrocytes amongst the extracellular matrix proteins and the cells to one another will 
enhance our ability to engineer a viable construct for articular cartilage. 
2.1.7 Summary 
 
Chondrocytes depend on their environment to aid in their expression of 
appropriate proteins.  It has been found that the interaction of integrin receptors with 
chondrocytes effects the production of extracellular molecules such as type II collagen 
and aggrecan.  Additionally, the presence of growth factors such as IGF-1, TGF-β1 and 
BMP-7 induce various signaling pathways that also aid in transducing phenotypic 




scaffold for chondrocytes.  The production of extracellular matrix proteins by 
chondrocytes has been studied.  As tissue engineers, it is advantageous to explore the 
possibility of how altering biomaterial properties affect the signaling cascades by 
activation of receptors and transduction through the cytoplasm.  This vital information 
will be able to aid in the future of engineering an appropriate biomaterial that can 




2.2 Polymeric Scaffolds for Tissue Engineering Applications* 
2.2.1 Introduction 
The incorporation of polymeric scaffolds in tissue regeneration occurred in the 
early 1980’s, and it continues to play a vital role in tissue engineering [118-120]. The 
function of a degradable scaffold is to act as a temporary support matrix for transplanted 
or host cells so as to restore, maintain or improve tissue. Scaffolds may be created from 
various types of materials, including polymers. There are two main classes of polymers, 
based upon their source: natural or synthetic. Polymeric scaffolds may be used to support 
a variety of cells for numerous tissues within the body. The design of a polymeric 
scaffold plays a significant role in proper cell growth. Therefore, several important 
properties must be considered: fabrication, structure, biocompatibility, biodegradability 
and mechanical strength. This review will discuss natural and synthetic polymers, as well 
as the properties that scaffolds exhibit. 
2.2.2 Natural Polymers for Scaffold Fabrication 
There are two major classes of natural polymers used as scaffolds: polypeptides 
and polysaccharides (Table 2.2, Figure 2.5). Natural polymers are typically 
biocompatible and enzymatically biodegradable. The main advantage for using natural 
polymers is that they contain bio-functional molecules that aid the attachment, 
proliferation, and differentiation of cells. However, disadvantages of natural polymers 
due exist. Depending upon the application, the previously mentioned enzymatic  
________________________________________________________________________ 
* This chapter was published as: Yoon DM and Fisher JP.  Polymeric Scaffolds for Tissue Engineering 
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degradation may inhibit function. Further, the rate of this degradation may not be easily 
controlled. Since the enzymatic activity varies between hosts, so will the degradation 
rate. Therefore it may be difficult to determine the lifespan of natural polymers in vivo. 
Additionally, natural polymers are often weak in terms of mechanical strength but 




Agarose is a polysaccharide polymer extracted from algae (Table 2.2, Figure 2.5). 
Its molecular structure contains an alternating copolymer linkage of 1,4-linked 3,6 
anhydro--l-galactose and 1,3-linked β-d-galactose [121]. Agarose is water-soluble due to 
the presence of hydroxyl groups. Two agarose chains interact with each other through 
hydrogen bonding to form a double helix. At low temperatures the agarose chains form a 
thermally reversible gel. Thus, at high temperatures agarose gels may be made water 
soluble. Many of the properties of agarose gels, particularly strength and permeability, 
can be adjusted by altering the concentration of agarose [121]. For example, low 
concentrations of agarose lead to a highly porous entangled structure with limited 
mechanical strength. Agarose in its native state is enzymatically degradable by agarases. 
For tissue culture systems, agarose hydrogels are widely investigated because 
they permit growth of cells and tissues in a three-dimensional suspension [122]. Agarose 
gels have been found to maintain chondrocytes, the predominant cell type in cartilage, in 
culture for 2-6 weeks [123]. Furthermore, agarose hydrogels embedded with 
chondrocytes allow the expression of type II collagen and proteoglycans [122, 124]. 




agarose gels have been investigated as a matrix for nerve regeneration [125, 126]. Dorsal 
root ganglia (DRG), a neural cell, has been encapsulated in agarose hydrogels. The 
influence of increasing porosity and incorporating charged biopolymers (e.g., chitosan) 
produced an increased in neurite extension of DRG isolated from chicks [126]. 
 
Alginate 
Alginate is a naturally derived water-soluble polysaccharide obtained from algae 
(Table 2.2, Figure 2.5) [121]. It is a polyanion composed of two repeating monomer 
units: β-d-mannuronate and -l-guluronate [127, 128]. Alginate is readily degraded at the 
β(1-4) linkage site, located in between the monomer units, by alginate lyases [127]. The 
physical and mechanical properties of alginate are dependent on the length and 
proportion of the guluronate block within the chain. Due to alginate’s polyelectrolytic 
nature, it readily forms into an ionotropic crosslinked hydrogel when exposed to divalent 
ions, the most common being calcium ions [129, 130].  Furthermore, alginate gels may be 
solubilized when these cations are removed or sequestered. This ease in gel reversibility 
allows alginate to be especially useful for studies requiring the retrieval of encapsulated 
cells. Alginate does not contain cellular recognition proteins, limiting cell attachment to 
the natural polymer. By crosslinking alginate with poly(ethylene glycol)-diamine the 
mechanical properties of alginate can be controlled and even improved [121]. 
A variety of different cells have been found to maintain their morphology in 
alginate scaffolds [127, 131-134]. The adhesion of fibroblasts in alginate sponges was 
found not to be affected by the porosity of the scaffold [131].  Chondrocytes embedded in 
alginate proliferated and expressed type II collagen [135].  Hepatocytes, the functional 




seeded in 3-dimensional porous alginate, albumin was secreted, indicating proper cell 
function [136]. Other types of cells studied in alginate include cardiomyocytes, rat 
marrow cells and Schwann cells [127, 134, 137]. 
 
Hyaluronic acid 
Hyaluronic acid (hyaluronan, HA) is a naturally occurring polysaccharide with a 
β(1-3) linkage of two sugar units: d-glucuronate and N-acetyl-d-glucosamine (Table 2.2, 
Figure 2.5).  Hyaluronic acid is an abundant glycosaminoglycan within the extracellular 
matrix of tissues that promotes early inflammation critical for wound healing [138]. 
Furthermore, hyaluronic acid is non-immunogenic and non-adhesive, making it an 
attractive option for biomedical applications. In dilute concentrations hyaluronic acid has 
a random coil structure which becomes entangled as its concentration increases [139].  
Some disadvantages of hyaluronic acid are that it is highly water soluble and it degrades 
rapidly by enzymes, such as hyaluronidase.  However, when fabricated into a hydrogel, 
hyaluronic acid is often more stable [121, 125, 138]. 
Currently, an ester derivative of hyaluronic acid has been used as a tissue 
engineering scaffold [125, 140, 141].  Adipose precursor cells proliferated and 
differentiated in HA sponges [140, 141].  Additionally, HA has been used for 
osteochondral repair by incorporating mesenchymal progenitor cells, which differentiate 
into osteoblasts and chondrocytes [125].  Furthermore, the interaction of chondrocytes 
embedded in HA has resulted in the expression of collagen type II, forming a tissue 







Chitosan is a partially deacetylated derivative of chitin, found in the exoskeleton 
of crustaceans and insects (Table 2.2, Figure 2.5).  It is a linear polysaccharide composed 
of β(1-4) linked d-glucosamine with randomly dispersed N-acteyl-d-glycosamine groups 
[121, 139, 142, 143].  Less than 40% of chitosan is comprised of the N-acteyl-d-
glycosamino group, which makes its molecular structure similar to glycosaminoglycans 
[121, 125].  Chitosan is easily degraded by enzymes such as chitosanase and lysozyme. 
Chitosan is catonic with semi-crystalline properties of a high charge density.  These 
attributes allow chitosan to be insoluble above pH 7 and fully soluble below pH 5.  At 
high pH solutions, chitosan can be gelled into strong fibers [143].  Furthermore, hydrogels 
can also be formed by either ionic bonding or covalent cross-linking, using crosslinking 
agents such as glutaraldehyde [121]. 
Chitosan is a well defined matrix and as a porous scaffold, hepatocytes were 
found to maintain a rounded morphology when cultured within chitosan scaffolds [144].  
Results showed an increase in albumin secretion as well as urea synthesis, vital metabolic 
activities of liver cells [144].  Additionally, crosslinking chitosan gels with 
glutaraldehyde showed increased urea formation by hepatocytes [145].  Furthermore, 
chitosan has shown promise as an orthopaedic scaffold.  When a sponge form of chitosan 
was seeded with rat osteoblasts, alkaline phosphatase production was detected, as well as 
bone spicules, indicating initial bone formation [146].  Also, chitosan scaffolds were 








Collagen is a major component of structural mammalian tissues (Table 2.2, Figure 
2.5).  Currently, 19 different types of collagen have been found, with the most abundant 
being type I collagen [148].  Collagen is composed of three polypeptide chains that 
intertwine with one another to form a triple helix.  The polypeptide chains have a 
repeating sequence of glycine-X-Y, where X and Y are most often found to be proline 
and hydroxyproline.  The chains are held together through hydrogen bonding of the 
peptide bond in glycine and an adjacent peptide carbonyl group [149].  The presence of 
adhesion domains allows collagen to display an attractive surface for cell attachment 
[148].  Some drawbacks in collagen are its high variability due to the numerous forms.  
Collagen is enzymatically biodegradable and has a tendency to degrade quickly, limiting 
its mechanical properties.  Crosslinking collagen with glutaraldehyde decreases its 
degradation rate [150]. 
Collagen naturally promotes healing wounds by promoting blood coagulation 
[148].  These attributes allow collagen to be used as a scaffold for cells within the 
epithelium, such as fibroblasts and keratinocytes [151-153].  Type II collagen is suitable 
for attaching chondrocytes and aiding in their proliferation and differentiation [154].  
Additionally, rat hepatocytes attached onto collagen-chitosan scaffolds secreted albumin, 
which confirms cell function [155].  Furthermore, corneal keratocytes cultured on 







Gelatin is a collagen derivative acquired by denaturing the triple-helix structure of 
collagen into single-strand molecules (Table 2.2, Figure 2.5).  It is water-soluble, and 
entangles easily to form into a gel through changes in temperature [121, 130].  Gelatin is 
broken down enzymatically by various collagenases.  The primary form of a gelatin 
scaffold is a hydrogel.  Stabilization of gelatin hydrogels occurs through chemical 
crosslinking with agents such as glutaraldehyde [139]. 
Gelatin has been used to support cells for orthopaedic applications.  Rat marrow 
stromal osteoblasts encapsulated in gelatin microparticles retained their phenotype [157].  
Also, porous gelatin scaffolds supported human adipose derived stem cell attachment and 
differentiation into a variety of cell lineages.  These constructs expressed a chondrogenic 
phenotype, indicated by the expression of hydroxyproline and glycosaminoglycans, both 
of which are present in the extracellular matrix of cartilage [158].  Furthermore, non-
orthopaedic cell types , such as respiratory epithelial cells and cardiocyocytes, have been 
shown to attach and form rounded morphologies in gelatin scaffolds [134, 159]. 
 
Silk 
Silks are fibers that have a protein polymer basis (Table 2.2, Figure 2.5) [160].  
There are two main sources of silks: spiders and silkworms.  The primary structure of 
silks is a repetitive sequence of proteins that are glycine-rich.  The secondary structure of 
silks is a β-sheet, which allows silks to exhibit enormous mechanical strength and is the 
primary reason for its strong interest as a scaffold.  Most types of silks undergo slow 
proteolytic degradation by proteases, such as chymotrypsin [160].  A drawback for using 




been a positive attachment and growth response of fibroblasts on fibroin silks.  And 
recently, osteoblasts seeded on silks have displayed bone growth characteristics [161, 
162]. 
2.2.3 Synthetic Polymers for Scaffold Fabrication 
Polymers that are chemically synthesized offer several notable advantages over 
natural-origin polymers. A major advantage of synthetic polymers is that they can be 
tailored to suit specific functions and thus exhibit controllable properties. Furthermore, 
since many synthetic polymers undergo hydrolytic degradation, a scaffold’s degradation 
rate should not vary significantly between hosts. The most common synthetic polymers 
are polyesters. Other types include polyanhydrides, polycarbonates and 
polyphosphazenes (Table 3, Figure 6). A significant disadvantage for using synthetic 
polymers is that some degrade into unfavorable products, often acids. At high 
concentrations of these degradation products, local acidity may increase, resulting in 




Poly(glycolic) acid (PGA) is a linear aliphatic polyester in the family of poly(α-
hydroxy esters) (Table 2.3, Figure 2.6). It is formed by ring-opening polymerization of 
cyclic diesters of glycolide [163]. Due to the crystallinity of glycolide, PGA is a highly 
crystalline polymer that has a high melting point (185-225 ºC) and low solubility in 
organic solvents [164, 165]. Further, PGA is hydrophilic and undergoes bulk degradation, 




glycolic acid, which is metabolized in the body. An unfortunate attribute of glycolic acid 
is that at high concentrations it lowers the pH of the surrounding tissue, causing 
inflammation and possible tissue damage [163]. 
Poly(glycolic) acid polymers has been investigated as a scaffold to support 
various types of cell growth. Bovine chondrocytes seeded on PGA scaffolds in vitro 
expressed sulfated glycosaminoglycans 25% more than native cartilage [166]. In vivo 
results using a mouse model were comparable to these in vitro results. Other studies 
seeded myofibroblasts and endothelial cells on a PGA fiber matrix. These cells persisted 
and expressed elastic filaments and collagen, demonstrating the potential use of PGA 
scaffolds for heart valve engineering [167]. Hepatocytes have also attached to PGA and 
initiated albumin synthesis [168]. Some investigations have coated PGA with other 
poly(α-hydroxy esters). Results with these scaffolds have shown that smooth muscle and 
endothelial cell growth may be supported [169]. 
 
Poly(l-lactic) acid 
Poly(l-lactic) acid (PLLA) is one of two isomeric forms of poly(lactic acid): d(-) 
and d,l(-). (Table 2.3, Figure 2.6) Similar to PGA, PLLA is classified as a linear poly(α-
hydroxy acid) that is formed by ring-opening polymerization of l-lactide [170]. PLLA is 
structurally similar to PGA, with the addition of a pendant methyl group. This group 
increases the hydrophobicity and lowers the melting temperature to 170-180 ºC for PLLA 
[165]. Additionally, the methyl group hinders the ester bond cleavage of PLLA, and thus 
decreasing the degradation rate [163]. PLLA typically undergoes bulk, hydrolytic ester-
linkage degradation, decomposing into lactic acid. The body is thought to excrete lactic 




hydrophobic nature of PLLA allows for protein absorption and cell adhesion making 
them suitable as scaffolds. 
In recent investigations, results have shown that the hydrophobic surface of PLLA 
has resulted in decreased adhesion of cells compared to other types of polymers, such as 
PGA [171]. However, PLLA has been found to support various cell types. Nerve stem 
cells seeded in PLLA fibers differentiated and expressed positive cues for neurite growth 
for potential regeneration of neurons [172]. Furthermore, human bladder smooth muscle 
cells seeded onto PLLA scaffolds also exhibited normal metabolic function and cell 
growth [133]. There has been similar work done with chondrocytes. The tissue 
engineered cartilage showed collagen, glycosaminoglycan, and elastin expression, vital 
for extracellular matrix formation [173]. 
 
Poly(D,L-lactic acid-co-glycolic acid) 
Poly(glycolic acid) and poly(lactic acid) can be copolymerized to form poly(D,L-
lactic acid-co-glycolic acid) (PLGA) (Table 2.3, Figure 2.6). This copolymer is 
amorphous, which decreases the degradation rate and mechanical strength of PLGA 
compared to PLLA. PLGA typically undergoes bulk degradation by ester hydrolysis. The 
degradation rate of PLGA can be controlled by adjusting the ratio of PLLA/PGA. 
However, it is important to note that know that the copolymer composition is not linearly 
related to the mechanical and degradation properties of PLGA. For example, a 50:50% 
ratio of PGA and PLLA typically degrades faster than either homopolymer [165, 174]. 
PLGA has been extensively researched as a tissue engineering scaffold and shown 
to support the growth of a variety of cell types. For instance, PLGA can facilitate human 




conducted with chondrocytes and osteoblastic cells [171, 175]. Osteoblastic cells seeded 
on PLGA scaffolds expressed collagen, fibronectin, laminin, and a variety of other 
extracellular matrix proteins, indicating proper cell function. Furthermore, PLGA 
promoted smooth muscle cell growth as well as the production of collagen and elastin 
[176]. Similar works showed enhancement of axon regeneration by murine neural cells 
seeded on PLGA scaffolds [177]. Additionally, an epithelial layer has been formed on 
PGLA by seeded enteroctyes derived from intestinal epithelial cells [178]. 
 
Poly(ε-caprolactone) 
Poly(ε-caprolactone) (PCL) is a aliphatic polyester with semi-crystalline 
properties (Table 2.3, Figure 2.6). PCL has repeating unit of one ester group and five 
methylene groups. It is highly water soluble with a melting temperature of 58-63 ºC [139, 
165]. PCL is formed through ring-opening polymerization, forming a degradable ester 
linkage. The degradation of PCL occurs by bulk or surface hydrolysis of these ester 
linkages, resulting in a byproduct of caproic acid. PCL degrades at a slow rate with 
results showing that it can persist in vivo for up to two years [165]. To increase the 
degradation rate, PCL has been copolymerized with collagen, poly(glycolic acid), 
poly(lactic acid), and polyethylene oxide [179-181]. The ease with which PCL can be 
copolymerized with a variety of polymers has made it an attractive component of 
polymeric scaffolds. 
PCL has been investigated as a stabilizing polymer on PGA scaffolds to aid in the 
formation of spherical aggregates by human biliary epithelial cells (hBEC). These hBECs 
proliferated on the synthetic scaffold and expressed phenotypic proteins, indicating cell 




human osteoblast and dermal fibroblast cell viability [182, 183]. The results with 
osteoblasts on porous PCL has shown a production of alkaline phosphatase, a marker of 
bone mineralization [182]. Also, dermal fibroblasts on mechanically stretched PCL films 
proliferated and maintained their rounded morphology [183]. 
 
Poly(propylene fumarate) 
Poly(propylene fumarate) (PPF) is a linear polyester with a repeating unit 
containing two ester groups and one unsaturated carbon-carbon double bond (Table 2.3, 
Figure 2.6). The hydrolysis of the ester bonds in PPF, forms fumaric acid and propylene 
glycol as the two primary degradation products. Covalent cross-linking of PPF through 
its double bond allows cured PPF to possess significant compressive and tensile strength. 
Furthermore, this crosslinking aids in the formation of a synthetic scaffold in situ [184, 
185]. Crosslinked PPF is a potential orthopaedic, especially bone, engineering material 
due to the strength that it exhibits [184]. Additional research has also been conducted with 
PPF copolymerized with PEG (PPF-co-PEG). This hydrophilic copolymer has been 
shown to support endothelial cell attachment and proliferation [186, 187].  
 
Polyorthoester 
A family of surface eroding polyorthoesters (POE) has been synthesized and 
studied for tissue engineering applications (Table 2.3, Figure 2.6). One particular form of 
POE has been considered as a scaffold. This type of POE is created by reacting ketene 
acetals with diols [188]. The hydrophobic nature of POE’s surface allows this polymer to 
undergo primarily surface degradation [125, 189]. By incorporating short acid groups, 




[189]. Furthermore, the hydrolysis of the orthoester linkages in POE is mostly sensitive 
to acids and is stable in bases [139, 174]. 
The surface eroding characteristics of POE has led to the research of this polymer 
for bone reconstruction [125, 190]. Surface degradation allows a scaffold to sustain 
mechanical support for the surrounding tissue since the bulk of the material remains 
structurally intact. In other studies, hepatocytes were grafted onto polyorthoesters and 
adhered to the surface of the synthetic scaffold [191]. 
 




Polyanhydrides are a class of hydrophobic polymers containing anhydride bonds, 
which are highly water reactive (Table 2.3, Figure 2.6) [192]. Polyanhydrides are also 
crystalline polymers, with a melting temperature of approximately 100 ºC [193]. 
Aliphatic polyanhydrides are synthesized by a dehydration reaction between diacids. The 
instability of the anhydride bond allows polyanhydrides to degrade within a period of 
weeks. The degradation rate is predictable for polyanhydrides and can be altered through 
changes in the hydrophobicity of the diacid building blocks [193]. Polyanhydrides are 
generally thought to degrade following a surface degradation mechanism. 
Similar to polyorthoesters, polyanhydrides has been investigated primarily for 
orthopaedic applications. However, the modest Young’s Modulus for entangled 
polyanhydride networks has limited their application in weight bearing environments 
[164]. This limitation resulted in further studies involving the formation of crosslinked 
polyanhydrides networks with incorporated imides [170, 194]. Scaffolds formed from 




(30-60 MPa), which are in the intermediate range of cortical and trabecular human bone 
(5-150 MPa) [164, 193-195]. 
 
Polyphosphazene 
Polyphosphazenes are a class of polymers formed from an inorganic backbone 
containing nitrogen and phosphorous atoms (Table 2.3, Figure 2.6). Polyphosphazene is 
hydrophobic and typically undergoes hydrolytic surface degradation into phosphate and 
ammonium salt byproducts. There are a variety of polyphosphazenes that may be 
synthesized, due to the numerous types of hydrolytically labile substituents that can be 
can be added to the phosphorous atoms [196]. These viable substituents allow the 
properties of polyphosphazenes to be extremely controllable. Nevertheless, most 
polyphosphazenes display a slow degradation rate in vivo [196]. 
A number of different polyphosphazenes has been synthesized for use as tissue 
engineering scaffolds. Due to its high strength and surface degradation properties, it has 
been particularly investigated as an orthopaedic biomaterial [197]. Osteoblast cells that 
support skeletal tissue formation has been seeded and proliferated on a three-dimensional 
polyphosphazene scaffold [198]. Additionally, poly(organo)phosphazenes has been 
studied as scaffolds for synthetic nerve grafts in peripheral nerve regeneration [199]. 
 
Polycarbonate 
Tyrosine-derived polycarbonate (P(DTR carbonate)) is an amorphous 
polycarbonate widely studied for biomedical applications (Table 2.3, Figure 2.6). The 
linear chain of P(DTR carbonate) contains a pendant R group, allowing it to be easily 




degradation: amide, carbonate, and ester [170, 200]. The carbonate and ester bonds readily 
degrade, with the former typically having a faster degradation rate. Nevertheless, the 
overall degradation time for P(DTR carbonate) can be months to years [201]. The ester 
bond degrades into carboxylic acid and alcohol, while the carbonate bond releases two 
alcohols and carbon dioxide [200]. The amide has been found to be relatively stable in 
vitro [200]. Overall, P(DTR carbonate) undergoes bulk degradation and its mechanical 
properties are determined by the pendant group [170, 200]. 
The slow degradation rate of polycarbonates has led to its investigation in 
orthopaedic tissue engineering applications. Additionally, P(DTR carbonate) elicits a 
response for bone ingrowth at the bone-polymer implant interface, supporting the use of 
P(DTR carbonate) as a bone scaffold.[201] Recent studies has shown that osteoblast cells 
do attach to the surface of P(DTR carbonate). Results indicate that these osteoblasts 
maintained their phenotype and rounded cell morphology[202]. 
 
Poly(ethylene glycol)/Poly(ethylene oxide) 
Poly(ethylene glycol) (PEG) is generally a linear-chained polymer consisting of 
an ethylene oxide repeating unit (-O-CH2-CH2)n (Table 2.3, Figure 2.6). Poly(ethylene 
oxide) (PEO) has the same backbone as PEG, but a longer chain length and thus a higher 
molecular weight [101, 203]. PEG is hydrophilic and synthesized by an anionic/cationic 
polymerization [121, 125].  The ability of PEG to act as a swelling polymer has primarily 
led to its function as a hydrogel, and in some instances an injectable hydrogel. 
Unfortunately, the linear chain form of PEG leads to rapid diffusion and low mechanical 
stability [125]. PEG networks may be created by attaching functional groups to the ends 




naturally non-degradable. However, PEG may be made degradable by copolymerization 
with hydrolytically or enzymatically degradable polymers [207]. 
The ease with which PEG may be modified, whether with crosslinkable groups 
for network formation or degradable groups for resorbable applications, has probably led 
to the widespread interest in PEG for tissue engineering or other biomedical applications.  
For example, PEG has been copolymerized with PLGA as well as alginate to form 
hydrogels. Results have shown that DNA content of chondrocytes on copolymerized 
PLGA-PEG increases as the percentage of degradable components becomes higher [208]. 
Similarly, islets of Langerhans in alginate-PEG hydrogels retained their viability and 
expressed function through insulin excretion [209]. 
 
Polyurethane 
Recent investigations have developed polyurethane polymers as scaffold 
materials. Polyurethane is an elastomeric polymer that is typically non-degradable (Table 
2.3, Figure 2.6). Positive attributes, such as flexible mechanical strength and 
biocompatibility, has led to the synthesis of degradable polyurethanes with non-toxic 
diisocyanate derivatives [164, 210-212]. Studies have shown that polyurethane scaffolds 
support cell attachment with chondrocytes, bone marrow stromal cells, and 
cardiomyocytes [212-214]. 
2.2.4 Scaffold Design Properties 
2.2.4.1 Fabrication 
There are two main considerations in the assembly of a polymeric tissue 




assembled into a bulk material. Second is the fabrication strategy. The chemical nature of 
the polymer often determines both the curing method and fabrication strategy. There are 
two main curing methods: polymer entanglement and polymer cross-linking. 
Entanglement usually involves intertwining long, linear polymer chains to form a loosely 
bound polymer network. An advantage of this type of method is that it is simple, 
allowing the polymer to be molded into a bulk material using heat, pressure or both. 
However, a disadvantage of this process is that the bulk material sometimes lacks 
significant mechanical strength. The second curing method is cross-linking, which 
involves the formation of covalent or ionic bonds between individual polymer chains. 
Typically either a radical or ion is needed to promote crosslinking along with an initiator, 
such as heat, light, chemical accelerant, or time. The advantages of crosslinked polymers 
are that they often have significant mechanical properties. Furthermore, crosslinked 
polymers may be injected into a tissue defect and cured in situ. However, one major 
disadvantage is the possible cytotoxicity issues with crosslinking systems. The multiple 
components used by crosslinking polymers as well as the necessary chemical reaction 
may lead to the use of cytotoxic components or the formation of cytotoxic reaction 
byproducts. 
There are two basic strategies of polymeric scaffold fabrication: prefabrication 
and in situ. Prefabrication structures are cured before implantation. This strategy is often 
preferred since it is formed outside the body, allowing the removal of cytotoxic and non-
biocompatible components prior to implantation. However, the notable disadvantage of 
prefabricated scaffolds is that it may not properly fit in a tissue defect site, causing gaps 




undesirable results, including fibrous tissue formation. Therefore, the deficiencies of 
prefabricated scaffolds have led to investigations towards in situ fabrication of a scaffold, 
which involves curing of a polymeric matrix within the tissue defect itself.  The 
deformability of an in situ fabricated matrix creates an interface between the scaffold and 
the surrounding tissue, facilitating tissue integration [215]. Furthermore, the implantation 
of an in situ fabricated scaffold may require as little as a narrow path for injection of the 
liquid scaffold, allowing minimally invasive surgery techniques to be utilized. A 
disadvantage of in situ fabrication of scaffolds is that the chemical or thermal means of 
curing the polymer can significantly affect the host tissue as well as any biological 
component of the engineered graft. 
 
2.2.4.2 Micro-structure 
Tissue regeneration through cell implantation in scaffolds is dependent on the 
micro-structure of the scaffold. Since most cells are anchorage dependent, the scaffold 
should possess properties that aid cell growth and facilitate attachment of a large cell 
population [163, 216]. To this end, a large scaffold surface area is typically favorable. 
Furthermore, highly porous scaffolds allow for an abundant number of cells to infiltrate 
the scaffold’s void space. Similarly, the continuity of the scaffold’s pores is important for 
proper transport of nutrients and cell migration. It is also generally advantageous for 
scaffolds to possess a large surface area to volume ratio. This ratio promotes the use of 
small diameter pores that are larger than the diameter of a cell. However, high porosities 
compromise the mechanical integrity of the polymeric scaffold. Clearly, balancing a 
scaffold’s surface area, void space, and mechanical integrity is a necessary challenge that 




Additionally, a polymer’s effectiveness as a scaffolding material is dependent on 
its interaction with transplanted or host cells. Thus the polymer’s surface properties 
should facilitate their attachment, proliferation, and (possible) differentiation. A strong 
cell adhesion favors the proliferation of cells, while a rounded morphology promotes 
their differentiation [163]. The hydrophilic nature of some polymers promotes a highly 
wettable surface and allows cells to be encapsulated by capillary action [217]. 
Furthermore, cellular attachment and function on polymeric scaffolds may be enhanced 
by providing a biomimetic surface through the incorporation of proteins and ligands. 
 
2.2.4.3 Macro-structure 
A scaffold can be formed into a number of different macro-structures including, 
fiber meshes, hydrogels, and foams. Fiber meshes are formed by weaving or knitting 
individual polymeric fibers into a three-dimensional structure and are attractive for tissue 
engineering as they provide a large surface area for cell attachment.[165] Furthermore, a 
fiber mesh scaffold structure mimics the properties of the extracellular matrix, allowing 
the diffusion of nutrients to cells and waste products from cells. A disadvantage to this 
form is the lack of structural stability. However, fiber bonding, which involves bonding at 
fiber cross points, has been introduced to create a more stable structure [163, 165, 218]. 
Hydrophilic polymers are often formed into hydrogels by physical polymer 
entanglements, secondary forces, or chemical crosslinking [101, 130]. The significant 
property of hydrogels is their ability to absorb a tremendous amount of water, up to a 
thousand times their own dry weight [130]. This aqueous environment, ideal for cell 
encapsulation and drug loading, has encouraged many investigations into hydrogels for 




often incorporated into strategies involving minimally invasive surgical techniques [149]. 
Some drawbacks to hydrogels are that they lack strong mechanical properties and they 
are difficult to sterilize [130, 149]. 
Foam and sponge scaffolds provide a macro-structural template for the cells to 
form into a three-dimensional tissue structure. There are several different processing 
techniques for porous constructs, including phase separation, emulsion freeze drying, gas 
foaming, and solvent casting/particulate leaching [163, 219-221]. A recent technology 
that has become of interest in tissue engineering is rapid prototyping or solid freeform 
fabrication. These techniques are quite exciting since they allow for the precise 
construction of scaffold architecture, often based upon a computer aided design 
model[222]. The most appropriate scaffold macro-structure is dependent on the type of 
the polymer utilized and the application (tissue) of interest. 
 
2.2.4.4 Biocompatibility 
One of the most essential properties of an engineered construct is its 
biocompatibility, or ability to not elicit a significant or prolonged inflammatory response. 
It is important to know that any injury will elicit some inflammatory response, and this is 
certainly true with the implantation of a polymeric scaffold.  However, this response 
should be limited and not prolonged. 
When a polymeric scaffold is implanted in a tissue, there is typically a three phase 
tissue response [223-225]. Phase I incorporates both acute and chronic inflammation, 
which occurs in a short period of time (1-2 weeks). Phase II involves the granulation of 
tissue, a foreign body reaction and fibrosis. The rate of phase II is primarily dependent on 




the bulk of the scaffold is lost. These phases are directly influenced by the properties of 
the polymeric scaffold. Therefore, it is important to evaluate a variety of scaffold 
properties including synthesis components, fabrication, micro-structure, and macro-
structure. It is a general thought that as the complexity of a scaffold system increases, the 
more likely it will result in a significant response by the body [190]. 
 
2.2.4.5 Biodegradability 
Most polymeric scaffolds are designed to provide temporary support and, 
therefore to be biodegradable.  Therefore, the degraded products of the scaffold must 
have a safe route for removal from the host. The rate of degradation is often affected by 
the properties of the polymeric scaffold including synthesis components, fabrication, 
micro-structure, and macro-structure. Most investigations intend for the scaffold 
degradation rate to closely follow the rate of tissue repair [139, 163]. However, this 
intention may be difficult to implement.  An alternative approach is to design the 
scaffold’s degradation rate so that it is quicker than the rate of degradation product 
removal, in an effort to minimize negative host responses.  
There are two types of degradation: surface and bulk [226]. Surface degradation 
of a scaffold is characterized by a gradual decrease in the dimensions of the scaffold with 
no change in its mechanical attributes. At a critical point during surface degradation, both 
size and mechanical properties of the scaffold decrease rapidly. Bulk degradation is 
characterized by loss of material throughout the scaffold’s volume during degradation.  
Thus, mechanical strength decreases during bulk degradation and is dependent on the 
degradation rate. Since bulk degradation maintains an intact surface, it may facilitate cell 




undergo surface degradation, since enzymes are generally too large to penetrate into the 
bulk of the scaffold. However, synthetic polymers can degrade by surface, bulk, or both, 
depending on its composition. 
 
2.2.4.6 Mechanical Strength 
Since many tissues undergo mechanical stresses and strains, the mechanical 
properties of a scaffold should be considered.  This is especially true for the engineering 
of weight bearing orthopaedic tissues.  In these instances, the scaffold must be able to 
provide support to the forces applied to both it and the surrounding tissues.  Furthermore, 
the mechanical properties of the polymeric scaffold should be retained until the 
regenerated tissue can assume its structural role [6].  In cases where mechanical forces 
are thought to be required for cell growth and phenotype expression, a scaffold which 
displays surface eroding properties may be preferred.  Alternatively, hydrophobic 
polymers tend to resist water absorption and thus sustain their strength longer than 
hydrophilic polymers. 
2.2.5 Summary 
Tissue engineering has emerged as a growing field for restoring, repairing, and 
regenerating tissue. Polymeric scaffolds especially have a profound impact on the 
possibilities of tissue engineering by providing structure for the attachment, proliferation, 
and differentiation of transplanted or host cells. These constructs have led to exciting and 
novel clinical options for the repair of tissues, including but not limited to skin, bone, 
cartilage, kidney, liver, nerve, and smooth muscle. To this end, scaffold properties must 




scaffold must allow invading cells to express proper functionality of the tissue being 
formed. Thus, tissue engineering research is continuously trying to enhance polymeric 




Table 2.2.  Properties of degradable natural homopolymers that have been utilized in the 












A Agarose entanglement enzymatic agarases oligosaccharides 
B Alginate crosslinking alginate lyases 
mannuronic acid 
and guluronic acid 




D Chitosan crosslinking enzymatic chitosanase glucosamines 
E Collagen crosslinking 
















Table 2.3.  Properties of degradable synthetic homopolymers that have been utilized in 













A Poly(glycolic acid) entanglement ester hydrolysis glycolic acid 




entanglement ester hydrolysis 
lactic acid and 
glycolic acid 




crosslinking ester hydrolysis 
fumaric acid and 
propylene glycol 
F Polyorthoester entanglement ester hydrolysis 
various acids 
depending upon R 
group 




depending upon R 
group 







ester and carbonate 
hydrolysis 






entanglement non-degradable not applicable 
K Polyurethane crosslinking 

































































































(D)  Chitosan  
 
Figure 2.5.  Repeating structural unit of degradable natural homopolymers under 
investigation as scaffold materials for tissue engineering applications.  (*Collagen and 
gelatin have variable sequences, but are predominately glycine, proline, and 
hydroxyproline.  **Silks have a glycine rich sequence, with glycine repeating every 
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(D)  Poly(caprolactone) 





























(F)  Polyorthoester  
 
Figure 2.6.  Repeating structural unit of degradable synthetic homopolymers under 




3 Effect of Construct Properties on Encapsulated 
Chondrocyte Expression of Insulin-like Growth Factor-1* 
3.1 Introduction 
Many biodegradable materials have been developed and investigated for use in 
reconstructing damaged articular cartilage [3, 6, 103, 116, 227]. Previous works indicate 
that hydrogels may be a preferred biomaterial for chondrocytes as they allow retention of 
the cells’ spherical morphology, which has been further correlated to stable phenotypic 
function [132, 228]. Alginate is a common natural biomaterial that has been used 
extensively to encapsulate chondrocytes [103, 116, 229, 230]. A hydrogel is formed by 
crosslinking the glucoronate chains of alginate with one another by divalent ions, such as 
calcium. An important property of this polymer is that it does not contain cell adhesive 
groups along its backbone, which allows for the investigation of cell function in the 
absence of matrix influences [231]. 
It is clear that external signals are critical for chondrocytes to maintain their 
phenotype [2, 33, 232, 233]. Many cartilage engineering strategies are based upon the 
delivery of exogenous signals to an encapsulated cell population [234, 235]. The type, 
concentration, and delivery profile of the exogenous signal is engineered to maintain 
phenotype, most importantly the synthesis of type II collagen. We propose a novel view  
of engineered tissues, where biomaterials are utilized to encourage endogenous 
expression of signaling proteins. Therefore, we hypothesize that an environment that 
facilitates signaling among an encapsulated cell population is critical to the successful 
development of engineered tissues. 
* This chapter was published as: Yoon DM, Hawkins, EC, Francke-Carroll, S, and Fisher JP. Effect of 
Construct Properties on Encapsulated Chondrocyte Expression of Insulin-like Growth Factor-1. 




In order to examine this hypothesis, we have begun investigating insulin-like 
growth factor-1 (IGF-1) signaling of chondrocytes encapsulated in alginate hydrogels. 
IGF-1 is a protein with a molecular weight of 7.5 kDa, which has a similar homology to 
insulin [37, 38, 40]. In cartilage, IGF-1 is generally viewed as an anabolic growth factor 
of chondrocytes, which has been shown to increase cartilage matrix synthesis [236, 237]. 
IGF-1 signaling, as well as most protein signaling, can be broadly characterized as 
involving multiple steps including expression, synthesis, secretion, transport, antagonist 
binding, and receptor binding [16]. This study focused on the endogenous expression of 
IGF-1 by chondrocytes. By varying the encapsulating alginate concentration, the water 
content of the alginate hydrogel was altered to affect the diffusional resistances of protein 
signals among neighboring chondrocytes. Additionally, the paracrine signaling distance 
between chondrocytes was modified by changing the density of chondrocytes 
encapsulated in each alginate hydrogel bead. We investigated the effects of these 
fabrication parameters, cell density and alginate concentration, on chondrocyte IGF-1 
expression and resulting phenotypic type II collagen expression over 8 days, using 
quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). The objectives 
for this work were to determine the (1) effect of cell density on chondrocyte IGF-1 
expression, (2) effect of alginate concentration on chondrocyte IGF-1 expression and (3) 
effect of IGF-1 expression on type II collagen expression by chondrocytes. 
3.2 Materials and Methods 
3.2.1 Cartilage Extraction and Chondrocyte Isolation 
Fresh cartilage was harvested from the metatarsal phalangeal joint of calves (15-




F-12 ham (DMEM/F12) media (Gibco, Carlsbad, CA) supplemented with 50 μg/mL 
ascorbic-2-phosphate (Sigma-Aldrich, St. Louis, MO), 1 mg/mL bovine serum albumin 
(Sigma-Aldrich), 1.2 mg/mL sodium bicarbonate (Sigma-Aldrich), 0.1% 
penicillin/streptomycin (Gibco), and 0.1% sodium pyruvate (Gibco) (supplemented 
DMEM). Cartilage was digested in 0.2% collagenase P (Roche, Indianapolis, IN) 
overnight at 37oC at 5% CO2. Chondrocytes were filtered through a 70 µm nylon mesh 
and washed three times in the supplemented DMEM/F12 media to remove residual 
undigested cartilage. The final chondrocyte solution was placed in supplemented 
DMEM/F12 media with 10% fetal bovine serum (FBS, Gibco). Cell counts and viability 
were assessed by visualization on a hemacytometer using a phase contrast microscope. 
Primary chondrocytes were incubated for approximately 2 hrs in supplemented 
DMEM/F12 media with 10% FBS before being encapsulated into alginate beads. 
3.2.2 Chondrocyte Encapsulation in Alginate and Culture 
Alginate solutions (0.8%, 1.2%, and 2.0% w/v) were prepared by mixing alginic 
acid sodium salt from brown algae (Sigma-Aldrich), 0.15 M NaCl, and 0.025 M HEPES 
(Sigma-Aldrich) in deionized water (pH 7.4). This solution was heated on a hot plate to 
dissolve the alginate and then stored for a day before being sterile filtered. Primary 
chondrocytes without preculture (0 d) were encapsulated at two different densities 
(25,000 and 100,000 cells/bead). The alginate and chondrocytes were passed through a 
22 gauge needle and injected into a continuously stirred 100 mM CaCl2 solution (Sigma-
Aldrich). Alginate beads, approximately 3 mm in diameter, formed instantaneously and 
were incubated for 15 min in the CaCl2 solution. The alginate beads were rinsed once 




containing approximately 500,000 total chondrocytes (20 or 5 beads). Chondrocytes 
encapsulated in the alginate beads were cultured in supplemented DMEM/F12 media and 
10% FBS at 37oC and 5% CO2. The media was changed every 2-3 days. Chondrocytes 
were isolated from the alginate beads for analysis at day 1, 4, and 8, by the addition of 3 
mL of 0.1 M ethyldiaminetetraacetic acid (Sigma-Aldrich) for 30 min at 37oC, which 
disrupted the bead by Ca2+ chelation. A cell pellet was formed by centrifugation at 
1000xg for 8 min. The chondrocyte pellet was resuspended in phosphate buffer saline 
(PBS) and used for subsequent assays. 
3.2.3 Alginate Water Content 
The water weights of alginate beads were determined by investigating their 
swollen weight (Ws) and dry weight (Wd). Ten alginate beads of 0.8%, 1.2%, and 2.0% 
w/v concentrations without cells were incubated in supplemented DMEM/F12 media 
with 10% FBS at 37oC. The media was changed every 2-3 days. At various time points, 
1, 4, and 8 d, the alginate beads were weighed (Ws). Then the alginate beads were placed 
into an oven at 100oC for approximately two weeks and weighed again (Wd). The water 
content percentage was calculated using the formula: (Ws-Wd)/Ws x 100%. Mean water 
contents and associated standard deviations (n = 3) are reported. 
3.2.4 Cell Viability 
Trypan blue stain 0.4% (Gibco) was used to distinguish viable cells from non-
viable cells. Viable cells appeared round and clear. Non-viable cells were asymmetrical 




by the following equation: (alive cells)/(alive cells + dead cells) x 100. Mean viabilities 
and associated standard deviations (n = 3) are reported. 
3.2.5 Histological Preparation 
Samples were collected and fixed in 4% paraformaldehyde (Sigma-Aldrich) and 
0.1 M sodium cacodylate (Sigma-Aldrich) buffer containing 10 mM CaCl2 at pH 7.4 and 
4oC. The beads were washed with 0.1 M sodium cacodylate buffer and 10 mM CaCl2 at 
pH 7.4 at room temperature for 24 hrs. The beads were placed in histological cassettes 
and dehydrated for histological processing by passing through an ascending ethanol line 
(40-100% for 20 min each) with two final xylene washes. The samples were embedded in 
paraffin (Paraplast X-tra, Fisher Scientific, Pittsburgh, PA) and cut into 4 µm thickness 
sections, which were then placed onto glass slides (Superfrost, Fisher Scientific). 
Sections were oven dried at 62oC for 2 hrs, deparaffinized in xylene (three times each for 
3 min), rehydrated in ethanol (100% and 95% for 1 min), and then stained with 
Hematoxylin and Eosin (H&E, Richard-Allan Scientific, Kalamazoo, MI) on an 
automated stainer (Richard Allan Microm HMS 760X). 
3.2.6 Chondrocyte Distribution Analysis 
The number of chondrocytes for each cell density case (e.g., 25,000 and 100,000 
cells/bead) in 1.2% w/v alginate beads was determined by counting the cells with 
microscopic examination of histological sections. Alginate beads with encapsulated 
chondrocytes were fixed, embedded, sectioned, and stained with H&E. Images were 




of cells was counted at these locations. Mean cells per area and associated standard 
deviations (n = 3) are reported. 
3.2.7 RNA Isolation 
Total RNA was isolated from chondrocytes using an RNeasy Mini Kit (QIAGEN, 
Valencia, CA). Chondrocytes were isolated as described above. The chondrocyte pellet 
was suspended in a lysis buffer with β-mercaptoethanol. The suspension was 
homogenized by both vortexing and using a syringe and needle. Ethanol was mixed into 
this solution and added to a spin column. Centrifugation adsorbed the RNA to the silica 
gel membrane within the spin column, which underwent several washes with buffer and 
DNA digestion by adding in a DNase solution (QIAGEN). Total RNA was eluted into 30 
μL of RNase free water (QIAGEN). 
3.2.8 Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
 
Isolated mRNA was reverse transcribed into cDNA using a cDNA Archive Kit 
(Applied Biosystems, Foster City, CA). Quantitative RT-PCR was performed by 
combining the cDNA solution with a Universal Master Mix (Applied Biosystems), as 
well as oligonucleotide primers and Taqman probes (Applied Biosystems) that were 
created for the genes of interest (IGF-1 and type II collagen) and the endogenous gene 
control (glyceraldehyde 3 phosphate dehydrogenase, GAPDH). The primer and probe 
sequences for IGF-1, type II collagen and GAPDH are detailed in Table 3.1. By using 
Taqman probes, the specific amplicon for the gene of interest was detected. The reaction 
was conducted on an ABI Prism 7000 sequence detector (Applied Biosystems) using 




at 94oC, and 1 min at 62oC. Each sample was studied in triplicate for each mRNA of 
interest. The gene expression for IGF-1 and type II collagen were analyzed for all of the 
groups in the study using a relative standard curve method, and were both normalized to 
GAPDH. The calibrator for each gene expression sample set data was selected to be the 
2.0% w/v alginate bead group with a 25,000 chondrocyte density population per bead for 
each gene of interest. This calibrator was chosen because the fold change values were the 
lowest, compared to all other groups. Therefore, the fold change amongst the samples 
was visually observable in the qRT-PCR data graphs. Mean fold changes and associated 
standard deviations (n = 3) are reported. 
3.2.9 Western Blotting 
Total protein concentration was extracted from the isolated cell pellet by using M-
Per Mammalian Protein Extraction Reagent (Pierce, Rockford, IL) and Halt Protease 
Inhibitor Cocktail (Pierce). All protein samples were stored in a -80oC freezer until their 
analysis. The protein solutions were dot blotted onto a nitrocellulose membrane and 
conjugated to the primary and secondary antibody solution as in a western blot. 
Supplemented media was used as a negative control to validate that signals obtained from 
the sample blots were only from protein produced by chondrocytes. Antibodies were used 
to study type II collagen and IGF-1 proteins. The primary antibodies are: anti-type II 
collagen (sheep polyclonal antibody, ab300, Abcam, Cambridge, MA) and anti-hIGF-1 
(goat IgG antibody, AF-291-NA, R&D Systems, Minneapolis, MN). The secondary 
antibodies are all horse radish peroxidase (HRP) conjugated: sheep polyclonal antibody 
(ab6795, Abcam) and goat IgG antibody (ab6885, Abcam). All antibodies were diluted 




using a SuperSignal West Pico Chemiluminescent Substrate (Pierce). The blots were 
scanned with a BioRad ChemiDoc XRS image analyzer. The same blots were used to 
detect type II collagen and IGF-1 respectively, which was achieved by using Restore 
Western Blot Stripping Buffer (Pierce). 
3.2.10  Statistical Analysis 
All experiments were conducted in triplicate. Data from all studies were analyzed 
using one-way analysis of variance (ANOVA) and Tukey’s multiple-comparison test 
were used to determine statistical significance with a 95% confidence interval (α = 0.05). 
The means and standard deviations are reported in each figure. 
3.3 Results 
3.3.1 Physical Characterization of Encapsulated Chondrocytes in 
Alginate Beads 
 
In order to demonstrate the effects of alginate concentration on the physical 
properties of the model beads, the water content of the beads was examined using 
concentrations of 0.8%, 1.2%, and 2.0% w/v alginate. These concentrations were chosen 
as they spanned the entire range in which alginate beads could be reproducibly fabricated. 
The results demonstrate that water content was greater than 95% for all conditions 
examined (Figure 3.1). The water content was greatest, over 97%, in the 0.8% w/v 
alginate beads. There was no significant change in water content for 0.8% w/v alginate 
over the course of the 8 d study (p = 0.59). The lowest water content, less than 96%, was 
found in the 2.0% w/v alginate beads. All three alginate concentrations were significantly 




determined to be similar amongst the 0.8% and 1.2% w/v alginate concentration beads, 
while both were significantly higher than 2.0% w/v alginate beads (p < 0.01). 
Primary bovine articular chondrocytes were then encapsulated in the three 
alginate bead classes and cell viability was investigated. A slight trend of decreased cell 
viability was observed during the 8 d study, however viability was found to be greater 
than 65% for all alginate concentrations and at all time points (Figure 3.2). The 
microscopic images taken at day 1 (Figure 3.3a and b) show chondrocytes at both cell 
densities encapsulated homogeneously throughout a 2.0% w/v alginate bead. 
Furthermore, the average distance between the cells was estimated for the two 
chondrocyte densities. Assuming a chondrocyte diameter of 15 µm [238, 239] and an 
alginate bead diameter of 3 mm (See Figure 3.3a and b), the average effective distance 
for paracrine signaling was calculated to be approximately 87.6 µm (25,000 cells/bead) 
and 49.6 µm (100,000 cells/bead).  See Appendix A for calculations of cell-to-cell 
distance. 
Histological analysis was utilized to examine chondrocyte morphology and 
distribution throughout the alginate beads. Figure 3.4 depicts a thin layer section of the 
chondrocytes within 1.2% w/v alginate beads with cell densities of 25,000 cells/bead 
(Figure 3.4a) and 100,000 cells/bead (Figure 3.4b). Chondrocyte nuclei were visible as 
dark violet circles. The surrounding alginate also stains a light violet color due to the 
alginate ionic charge. Cell distribution may be qualitatively described by measuring the 
number of cells per area at a radius of 0, 0.75, and 1.50 mm out from the center of the 
alginate bead (Figure 3.5). For both the 25,000 and 100,000 cell density cases, there was 




examined (p = 0.04 and p = 0.05, respectively). When comparing the 25,000 and 100,000 
cell densities, the average number of cells per area was determined to be statistically 
different at each radius examined (p < 0.01), as expected. 
3.3.2 IGF-1 mRNA Expression 
Over the course of 8 d, IGF-1 mRNA expression was detected for chondrocytes 
encapsulated in all alginate concentrations. For the 25,000 density case, there was an 
increasing trend of IGF-1 mRNA expression in all alginate concentrations (Figure 3.6). 
During the 8 d study, encapsulated chondrocytes exhibited approximately a 3 fold 
increase in IGF-1 expression for the 0.8% w/v alginate beads, a 10 fold increase for the 
1.2% w/v alginate beads, and a 35 fold increase for the 2.0% w/v alginate beads. At day 
1, the IGF-1 fold change values for all of the alginate concentrations were similar (p = 
0.08). At day 8, there was no statistical difference between the 0.8% and 1.2% w/v 
alginate concentration case (p = 0.02) and both were greater than the 1.2% w/v alginate 
case (p < 0.01). 
Overall, the encapsulation of 100,000 chondrocytes per alginate bead 
demonstrated significantly higher IGF-1 mRNA expression when compared to the lower 
cell density case (Figure 3.7). At this higher cell density, chondrocytes showed an 
increased level of IGF-1 mRNA expression for all alginate cases and at all time points, 
except for the 0.8% w/v alginate group at day 1. 
For the 100,000 density case, the 0.8% w/v alginate group showed similar fold 
change levels for IGF-1 at all time points (p = 0.05). Alternatively, the 1.2% and 2.0% 
alginate beads showed increased IGF-1 expression from day 1 to 8. However, in both of 




time point, the 2.0% w/v alginate group’s IGF-1 fold change levels are greater than that 
for the 0.8% w/v alginate group (p < 0.01). 
3.3.3 Type II Collagen mRNA Expression 
Type II collagen mRNA expression was detected for chondrocytes encapsulated 
in all alginate concentrations and time points. For the 25,000 chondrocyte density case 
(Figure 3.8), cells encapsulated in 0.8% w/v alginate beads demonstrated a trend of 
decreasing type II collagen mRNA expression over the course of 8 d. Chondrocytes 
encapsulated in 1.2% w/v alginate demonstrated similar type II collagen expression levels 
at all time points examined (p = 0.10). Type II collagen fold change levels for the 2.0% 
w/v alginate case were greatest at day 4 but similar between day 1 and 8 (p < 0.01). 
Overall, and similar to the IGF-1 study, the encapsulation of 100,000 
chondrocytes per alginate bead demonstrated higher type II collagen mRNA expression 
when compared to the lower cell density case (Figure 15). Specifically, chondrocytes 
encapsulated at a 100,000 cells/bead density had a greater type II collagen mRNA 
expression for 1.2% and 2.0% alginate concentrations compared to the lower cell density 
case (p < 0.05). 
Considering the results of the 100,000 chondrocyte density cases alone, the type II 
collagen mRNA expression levels for 0.8% and 2.0% w/v alginate groups did not 
significantly change over the course of the 8 d study (p = 0.22 and p = 0.14, respectively). 
However, the chondrocytes encapsulated in 1.2% w/v alginate showed mRNA expression 
levels to be greatest at day 8 compared to day 1 and 4, which were similar in value (p < 
0.01). There was no significant difference between the any of the alginate cases at day 8 




3.3.4 IGF-1 and Type II Collagen Protein Expression 
The intracellular proteins of chondrocytes in all of the sample groups were 
extracted for detection of IGF-1 and type II collagen. Results indicate that both proteins 
were being synthesized by chondrocytes from every sample group during the 8 d study. 
Figure 3.10a shows the IGF-1 protein dot blot for chondrocytes in all of the alginate bead 
cases. The production of type II collagen was supported by the dot blot pictured in Figure 
3.10b. These results showed that protein production occurred, but no correlation was 
observed with mRNA expression levels by chondrocytes. This is expected as the dot blot 
method is not quantitative. 
3.4 Discussion 
In order to create an engineered articular cartilage construct based upon 
transplanted chondrocytes, it is essential to develop the proper environmental conditions 
for chondrocytes to retain their phenotype. Currently, investigators propose cartilage 
engineering strategies that ensure a stable chondrocyte phenotype by delivering 
exogenous signals to a transplanted cell population [234, 240]. We aimed to investigate 
whether construct properties may be altered to enhance endogenous signal expression, in 
order to ensure a stable chondrocyte population. In particular, this work investigates the 
effect of construct properties on chondrocyte expression of IGF-1 within an alginate 
hydrogel. The two properties, cell density and alginate density, were chosen to be varied 
simultaneously since each has a limited working range. Cell density is bounded at a lower 
limit by a reasonable cell population for analysis and at a higher limit by the ability to 




limited at both the lower and higher limit by concentrations that can produce beads under 
standard conditions. Nevertheless, by varying cell density, the cell-to-cell distance was 
altered, which therefore influenced paracrine signaling distance. Furthermore, by varying 
alginate density, the water content or soluble protein transport resistance was changed. 
Using these parameters, the following three objectives were addressed in this study: (1) 
effect of cell density on IGF-1 expression by chondrocytes in alginate beads, (2) effect of 
alginate concentration on IGF-1 expression by chondrocytes and (3) effect of IGF-1 
expression on type II collagen expression by encapsulated chondrocytes. 
To this end, chondrocytes were encapsulated homogenously within the alginate 
hydrogel beads, with the homogenous distribution of chondrocytes demonstrated by 
histological examination of cells per area (Figure 3.5). For both cell density cases, the 
average number of cells per area was similar at each of the three radii examined, 
indicating that the chondrocytes were distributed homogenously. Furthermore, a 
significant difference in cell density was observed between the 25,000 and 100,000 
cells/bead, as expected. 
The results of this work demonstrate that cell density plays a significant role in 
augmenting IGF-1 expression. Over the 8 d study, a generally increasing trend of IGF-1 
expression by chondrocytes was found for both density cases and all of the alginate 
concentrations. However, the overall expression of IGF-1 was dramatically greater for 
the 100,000 versus 25,000 cell density case, with an order of magnitude difference 
demonstrated by chondrocytes in these two cases (Figures 3.6 and 3.7). This result 
indicates that a difference in the paracrine signaling distance between chondrocytes 




increased levels of IGF-1 mRNA expression. We propose that increased cell density 
enhances chondrocyte competition for IGF-1, thereby inducing the endogenous 
expression of IGF-1. 
Secondly, the results indicate that IGF-1 expression by chondrocytes is strongly 
augmented by alginate hydrogel concentrations, but only at a high cell density (Figure 
3.7). Increasing alginate concentration to 2.0% w/v is associated with a slight, but 
significant decrease in water content, indicating an increase in diffusional resistances of 
soluble molecules. The effect of alginate concentration is not seen at the 25,000 cell 
density level. However, at the 100,000 cell density level IGF-1 mRNA expression is 
significantly altered by alginate concentration. These results indicate that changing 
construct properties, particularly by increasing both cell density and matrix concentration, 
may be utilized to enhance IGF-1 mRNA expression. 
Finally, we examined the effect of IGF-1 expression on chondrocyte phenotype, 
as measured by type II collagen expression (Figures 3.8 and 3.9). Although 
understanding the influence of construct parameters on molecular signaling is significant, 
the resulting affect upon cell phenotype is critical.  In all cases, type II collagen 
expression was observed, demonstrating phenotypic function of the chondrocytes. 
Similar to IGF-1 mRNA expression, chondrocytes encapsulated at a density of 100,000 
cells/bead expressed type II collagen mRNA at a significantly higher level than at a 
density of 25,000 cells/bead, demonstrating the major influence of cell density on cell 
function. Also similar to the IGF-1 results, there was no observable trend for type II 
collagen expression at the low density case, while at the high density case type II 




results indicate that alterations in cell density and polymer concentration do alter 
encapsulated chondrocyte IGF-1 expression and, furthermore, chondrocyte function, as 
demonstrated by type II collagen expression. 
3.5 Conclusion 
The optimal construct for chondrocyte transplantation is of great interest in the 
biomaterials community. While most approaches for studying chondrocytes in these 
engineered environments focus on exogenous protein delivery, we present a novel 
approach in understanding chondrocytes within a biomaterial by focusing on the 
endogenous signaling. The results of this work demonstrate that both cell density and 
alginate concentration altered IGF-1 mRNA expression by chondrocytes encapsulated 
within alginate beads. Furthermore, IGF-1 mRNA expression trends were shown to 





Table 3.1.  Primer and Probe Sequences for Quantitative RT-PCR. 
 
Protein Segment Sequence 
Forward Primer CCCAGACAGGAATCGTGGAT 
Reverse Primer ACATCTCCAGCCTCCTCAGATC
Insulin-Like Growth Factor-1 
(IGF-1) 
Probe CTGCTTCCGGAGCTG 
Forward Primer CGGGCTGAGGGCAACA 
Reverse Primer CGTGCAGCCATCCTTCAGA Type II Collagen 
Probe CAGGTTCACATATACCG 
Forward Primer TGCCGCCTGGAGAAACC 




























Figure 3.1.  Percentage of water content in 0.8%, 1.2%, and 2.0% w/v alginate bead 
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Figure 3.2.  Percentage of chondrocyte viability when encapsulated in 0.8%, 1.2%, and 
2.0% w/v alginate bead concentrations for 25,000 and 100,000 cell density over the 8 d 
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Figure 3.3.  Microscopy images of 2.0% w/v alginate beads with (a) 25,000 
chondrocytes/bead and (b) 100,000 chondroctyes/bead at day 1 in two different 












Figure 3.4.  Hematoxylin and eosin stained sections of 1.2% w/v alginate bead with (a) 
25,000 and (b) 100,000 chondrocyte density encapsulated after 8 and 4 d of culture, 
respectively. The alginate matrix stained with a light violet hue, while the chondrocytes 








































Figure 3.5.  Average number of cells per area determined from hematoxylin and eosin 
stained 1.2% w/v alginate beads at 25,000 and 100,000 chondrocyte densities. Both cell 
densities investigated are associated with a homogenous cell distribution throughout the 



























Figure 3.6.  IGF-1 mRNA expression for 0.8%, 1.2%, and 2.0% w/v alginate hydrogels 
with an initial chondrocyte density of 25,000 cells per bead over 8 d. An increase in IGF-
1 mRNA expression by encapsulated chondrocytes occurs for all alginate concentrations 
from day 1 to 8. The calibrator for all the samples tested for IGF-1 expression is indicated 


























Figure 3.7.  IGF-1 mRNA expression for 0.8%, 1.2%, and 2.0% w/v alginate hydrogels 
with an initial chondrocyte density of 100,000 cells per bead over 8 d. In general, 
chondrocytes encapsulated in all alginate bead concentrations increased their mRNA 



































Figure 3.8.  Type II collagen mRNA expression for 0.8%, 1.2%, and 2.0% w/v alginate 
hydrogels with an initial chondrocyte density of 25,000 cells per bead over 8 d. 
Chondrocytes sustain their mRNA expression of type II collagen in various alginate bead 
concentrations. The calibrator for all the samples tested for type II collagen expression is 


































Figure 3.9.  Type II collagen mRNA expression for 0.8%, 1.2%, and 2.0% w/v alginate 
hydrogels with an initial chondrocyte density of 100,000 cells per bead over 8 d. 
Phenotypic type II collagen mRNA expression of encapsulated chondrocytes within all 
alginate bead concentrations is observed. The means and standard deviations are reported 











Figure 3.10.  Dot blots of intracellular protein samples from a density of 25,000 (A, C 
and E) and 100,000 (B, D and F) chondrocytes/bead as well as all alginate 
concentrations, 0.8% w/v (A and B), 1.2% w/v (C and D), and 2.0% w/v (E and F). These 
samples are taken from day 1, 4, and 8 time points, where (a) indicates IGF-1 protein 




4 Effects of Exogenous IGF-1 Delivery on the Early 
Expression of IGF-1 Signaling Molecules by Alginate 
Embedded Chondrocytes* 
4.1 Introduction 
A fundamental role of chondrocytes is to synthesize the extracellular matrix 
proteins and biomolecules within articular cartilage.  However, when this matrix is 
disrupted, chondrocytes are often unable to reestablish healthy cartilage tissue.  As a 
result, both researchers and clinicians are investigating ways to engineer functional 
cartilage tissue.  While an understanding of both chemical and mechanical mechanisms 
are important to achieve this objective, here we focused on molecular factors.  In 
particular, our goal was to determine how growth factor stimulation of chondrocytes 
embedded in an alginate hydrogel affects chondrocyte upstream signaling and therefore 
phenotypic function. 
A multitude of intercellular signaling proteins have been identified within 
articular cartilage.  For example, insulin-like growth factor-1 (IGF-1) is a major anabolic 
growth factor of articular cartilage that has been found to enhance chondrocyte 
proliferation as well as the synthesis of vital extracellular matrix proteins, including type 
II collagen.[2, 236, 237]  IGF-1 is a small, 7.5 kDa protein with a half life of 10 minutes 
when it is in free form.[241]  However, the stability of free IGF-1 can be enhanced by 
binding to insulin-like growth factor binding proteins (IGFBPs).[40, 242]  There are 
several binding proteins with a predominant one being IGFBP-3 in serum.[40, 43, 243-
246]  Proteolytic enzymes in the synovial fluid as well as those released by chondrocytes  
* This chapter was published as: Yoon DM and Fisher JP. Effects of Exogenous IGF-1 Delivery on the 
Early Expression of IGF-1 Signaling Molecules by Alginate Embedded Chondrocytes. Tissue Engineering 




can break down the IGFBPs, therefore allowing IGF-1 to bind to the insulin-like growth 
factor-1 receptor (IGF-1R), a tyrosine kinase membrane receptor.[38, 43]  The activation 
of IGF-1R results in a cascade of several intracellular pathways of chondrocytes, 
typically leading to matrix expression.[40, 107, 247] 
Previous works have shown that glycosaminoglycans, proteoglycans, and type II 
collagen protein synthesis as well as mRNA expression occurs in cartilage extracts, 
chondrocytes in monolayer, and chondrocytes in alginate when incubated with exogenous 
IGF-1.[230, 236, 237, 248]  A standard concentration range of 0-100 ng/mL has been 
used in most experiments with varying culture times of up to 6 days.[230, 236, 237, 248, 
249]  Results have shown that exogenous IGF-1 delivery to chondrocytes in monolayer, 
resulted in an increase of aggrecan, type II collagen, and IGF-1 mRNA levels after 72 
hours.[248]  Similarly, other investigations focused on how culturing conditions for 10 
days affected chondrocytes that were reseeded in monolayer and introduced to 50 ng/mL 
IGF-1.  The results here showed that pre-cultured chondrocytes in alginate experienced 
higher total RNA levels of IGF-1, IGF-1R and IGFBP-2 as well as phenotypic mRNA 
expression than cultures in monolayer.[249]  These studies indicate the importance of 
understanding IGF-1 signaling of chondrocytes.  However, they focus on the short term 
effects (hours to days) of exogenous IGF-1 upon chondrocytes in monolayer. 
Our objective here is to examine the effects of signal delivery on a system which 
is relevant to many tissue engineering strategies, therefore involving culture of articular 
chondrocytes for at least one week and within a 3D scaffold.  To the best of our 
knowledge, this is the first reported study that thoroughly investigates endogenous 




Alginate was chosen as the biomaterial because it allows chondrocytes to maintain their 
spherical morphology.[106, 116, 250]  Additionally, alginate contains no amine groups or 
cellular recognition proteins that factor into charge mediated adhesion.[251, 252]  Thus, 
the mostly benign properties of alginate allow one to focus particularly upon the delivery 
of IGF-1 on the chondrocytes.  We have previously shown that endogenous IGF-1 
expression was enhanced in a 2.0% w/v alginate concentration with a density of 100,000 
chondrocytes per bead.[253]  Utilizing these previous results, we examined how 
exogenous IGF-1 affects expression of upstream IGF-1 signaling molecules.  Our specific 
objectives are to investigate the effects of exogenous IGF-1 delivery upon (1) 
endogenous IGF-1, IGF-1R and IGFBP-3 expression as well as (2) chondrocyte 
phenotype, as demonstrated by type II collagen and type I collagen expression. 
4.2 Materials and Methods 
4.2.1 Cartilage Extraction and Chondrocyte Isolation 
Slices of cartilage were removed from the metatarsal phanlangeal joint of calves 
(15-18 weeks old) and then washed in Dulbecco’s Modified Eagle Medium/Nutrient 
Mixture F-12 Ham (DMEM/F12) media (Gibco, Carlsbad, CA), which contained the 
following additives: 50 μg/mL ascorbic-2-phosphate (Sigma-Aldrich, St. Louis, MO), 1 
mg/mL bovine serum albumin (Sigma-Aldrich), 1.2 mg/mL sodium bicarbonate (Sigma-
Aldrich), 0.1% penicillin/streptomycin (Gibco) and 0.1% sodium pyruvate (Gibco).  
Chondrocytes were isolated by digesting the cartilage in 0.2% collagenase P (Roche, 
Basel, Switzerland) overnight at 37 oC and then filtered through a 40 µm nylon mesh to 
remove any undigested tissue.  Primary chondrocytes without pre-culture were utilized 




4.2.2 Chondrocyte Encapsulation in Alginate and Culture 
Chondrocyte culture techniques follow closely from previously published 
work.[253]  Briefly, 2.0% w/v alginate solution was prepared by mixing and heating 
alginic acid sodium salt from brown algae (Sigma-Aldrich), 0.15M sodium chloride and 
0.025M HEPES (Sigma-Aldrich) into deionized water (pH 7.4) and then sterile filtered.  
The alginate solution was mixed with chondrocytes and injected through a 0.22 gauge 
syringe into a continuously stirred 100mM calcium chloride (Sigma-Aldrich) to create a 
density of 100,000 cells per bead.  The beads were incubated in the calcium chloride 
solution and DMEM/F12 for 15 minutes each.  Afterwards, 5 beads were transferred into 
each well of a 6-well plate and cultured in DMEM/F12 media and 10% fetal bovine 
serum (supplemented DMEM/F12 media) at 37oC (day 0) for 2 days.  This was done to 
stabilize the chondrocytes within the hydrogel.[132, 254]  The media was changed on day 
3 with supplemented DMEM/F12 media and human insulin-like growth factor-1 (IGF-1; 
R&D Systems, Minneapolis, MN).  Human IGF-1 was used because it has a similar 
homology to bovine IGF-1.[255]  The following IGF-1 concentrations were studied: 0, 
10, 50, and 100 ng/mL.  In this paper, 0 ng/mL IGF-1 case will be labeled as the control 
group, while the 10, 50, and 100 ng/mL IGF-1 cases will be referred to as the 
experimental groups. The media and IGF-1 were changed daily.  Chondrocytes were 
isolated from five alginate beads for analysis at day 1, 4, and 8 by the addition of 3 mL of 
0.1M ethylenediaminetetraacetic acid (EDTA) for 30 min at 37oC.  A cell pellet was 
formed by centrifugation and then resuspended in PBS and split for RNA and DNA 




Labconco Freeze Dry System/Lyph Lock 4.5 (Labconco, Kansas City, MO) and then 
weighed to determine the dry weight. 
4.2.3 RNA Isolation 
Total RNA was isolated from chondrocytes using the RNeasy Plus Mini Kit 
(Qiagen, Valencia, CA).  Total RNA was eluted into RNase free water and detected using 
a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).  
The RNA concentrations at 1, 4, and 8 d for all groups were approximately 50 ng/uL, 200 
ng/uL, and 450 ng/uL respectively. 
4.2.4 DNA Isolation and Quantification 
Total DNA was isolated from chondrocytes using a DNeasy Blood and Tissue Kit 
(Qiagen).  Total DNA was eluted in 400 uL of Buffer AE.  This DNA solution was 
incubated with PicoGreen to determine the amount of double stranded DNA (dsDNA) by 
using a Quant-iT PicoGreen dsDNA Assay kit (Invitrogen, Carlsbad, CA).  The samples 
were excited at 480nm and evaluated at an emission of 520nm using a fluorescence 
microplate reader (Molecular Devices SpectraMax M5, Sunnyvale, CA).  A standard 
curve was prepared from a known concentration of DNA provided in the kit and this 
curve was used to quantify nanograms of DNA per bead. 
4.2.5 Histology 
All samples were collected and fixed in 4% paraformaldehyde / 0.1M sodium 
cacodylate buffer containing 10mM CaCl2 (pH 7.4) for 24 hours at 4
oC.  The beads were 




room temperature.  Afterwards, the beads were dehydrated in a series of ethanol 
concentrations (40-100%) with a final xylene wash.  The samples were embedded in 
Paraplast X-tra paraffin (Fisher Scientific, Pittsburgh, PA) and cut into 4µm thickness 
sections, which were placed onto charged microscope slides and kept at 4oC until 
staining. 
4.2.6 Histochemical Staining 
Sections were oven dried for 2 hours at 60oC, deparaffinized in Citrisolv Hybrid 
(Fisher Scientific) two times for 3 minutes, rehydrated in 100% and 95% ethanol for 1 
minute each, and rinsed in distilled water.  Sections were stained with Safranin-O (0.1%; 
Poly Scientific, Bay Shore, NY) and counter stained with Fast Green (0.001%, Fisher 
Scientific, Pittsburgh, PA). 
4.2.7 Immunohistochemistry 
Sections were dried at 60oC for 1 hour, deparaffinized in Citrisolv Hybrid two 
times for 5 minutes, rehydrated in a descending line of ethanol (100%, 95%, and 70% for 
3 minutes each), rinsed in tap water, and then rinsed in deionized water.  The sections 
were then incubated with PEROXIDAZED1 (Biocare, Concord, CA), an endogenous 
peroxidase blocker, and BackgroundSNIPER1 (Biocare), a blocking reagent.  The 
sections were then stained with antibodies that detect the presence of type II collagen and 
IGF-1 proteins.  The primary antibodies are: anti-type II collagen (rabbit polyclonal 
antibody, ab300, Abcam, Cambridge, MA) and anti-hIGF-1 (goat IgG antibody, AF-291-
NA, R&D Systems).  Each antibody was diluted at 1:200.  A HISTOSTAIN®-SP kit 




a horseradish peroxidase (HRP)-strepavidin-biotin system.  This complex formation was 
detected by a 3,3’-diaminobenzidine tetrahydrochloride (DAB) chromogen.  For IGF-1, a 
HRP conjugated secondary antibody (goat IgG antibody, ab6885, Abcam) was used at a 
dilution of 500 times and detected by a histochemical substrate (Liquid DAB Substrate 
Kit, Zymed).  All samples were counterstained with hematoxylin, dehydrated in 95% and 
100% ethanol twice for 1 minute each, cleared in Citrisolv Hybrid twice for 1 minute, 
and coverslipped using Permount (Fisher Scientific).  To show non-specific staining, 
samples were not incubated with the primary antibody and then incubated with the 
secondary antibody for each protein (negative staining control). 
4.2.8 Quantitative Reverse Transcriptase-Polymerase Chain Reaction 
(qRT-PCR) 
 
The total isolated mRNA for all groups at all time points was reverse transcribed 
using a cDNA Archive Kit, which can convert up to 10 μg of RNA to cDNA (Applied 
Biosystems, Foster City, CA).  Quantitative RT-PCR was performed by combining the 
cDNA with a Universal Master Mix (Applied Biosystems), as well as oligonucleotide 
primers and probes (Applied Biosystems) that were created for the genes of interest (IGF-
1, IGF-1R, IGFBP-3, type I collagen and type II collagen) and the endogenous gene 
control (glyceraldehyde 3 phosphate dehydrogenase, GAPDH).  The same primer and 
probes for IGF-1, type II collagen and GAPDH were used from previous work.  The 
sequences for the forward primers for IGF-1R, IGFBP-3, and type I collagen are: 5’ 
TGCATGGTGGCCGAAGA 3’, 5’ CGCCTGCGCCCTTACC 3’, and 5’ 
AGAACCCAGCTCGCACATG 3’. The reverse primer sequences for IGF-1R, IGFBP-3, 




TTCTTCCGACTCACTGCCATT 3’, and 5’ CAGTAGTAACCACTGCTCCATTCTG 
3’. The probe sequences for IGF-1R, IGFBP-3, and type I collagen are: 5’ 
TTCACAGTCAAAATC 3’, 5’ CTACCGTCCGCGTCAG 3’ and 5’ 
AGACTTGAGACTCAGCC 3’.  The reaction was conducted on an ABI Prism 7000 
sequence detector (Applied Biosystems), using thermal conditions of 2 min at 50oC, 30 
min at 60oC, 5 min at 95oC, and 40 cycles of 20 s at 94oC and 1 min at 62oC.  The 
expression for each gene was analyzed for all the groups in the study using a relative 
standard curve method, which were normalized to GAPDH.  The calibration for the data 
obtained for each gene expression sample set was analyzed to the control sample (0 
ng/mL IGF-1 group).  This calibrator was chosen to represent the gene expressions data 
appropriately. 
4.2.9 Statistical Analysis 
Two separate and independent experiments were performed.  The trends obtained 
in both experiments were similar.  However, the data presented here is derived from a 
single experiment since the primary cell populations are variable.  Data from all studies 
were analyzed using ANOVA and Tukey’s multiple-comparison test.  The means and 
standard deviations are reported; samples were analyzed in triplicate (n = 3). 
4.3 Results 
4.3.1 Physical Characterization of Embedded Chondrocytes 
The water content of alginate (~96-97%) did not change significantly during the 8 
day study for all the groups.  However, upon calculating the dry weight of each alginate 




was similar for all groups at day 1 and 4, there was a significant difference between the 
control group versus the experimental groups at day 8 (p  <  0.01).  
The change in physical appearance of the alginate bead over the course of the 
study can be visually seen in the Safranin-O/Fast Green stained images (Figure 4.2).  
Chondrocyte nuclei are observed as a gray hue, while the alginate turned into a bright 
orange color and matrix proteins were colored a lighter orange hue.  At day 1 of the 
experiment, chondrocytes were homogenously embedded within the alginate bead for all 
conditions, which has also been seen in previous work.  Figure 4.2a depicts a typical 
section of chondrocytes in an alginate bead at day 1 of the experiment.  When this image 
is compared to the pictures of all the groups at day 8 (Figure 4.2b, c, d, and e), clustering 
is observed at the outer border of the bead and distributed uniformly throughout the 
periphery.  This clustering affect seems to be more predominate in the groups that 
received exogenous IGF-1 (Figure 4.2c, d, and e).  To investigate the effect of IGF-1 on 
chondrocyte proliferation, DNA levels were measured in each bead.  Over the 8 days, 
there was an increasing trend of DNA for all groups (Figure 4.3).  However, at each time 
point all the groups had similar amounts of DNA. 
4.3.2 mRNA Expression of Endogenous IGF-1 Signaling Molecules 
IGF-1 mRNA expression occurred in all the sample groups during the study 
(Figure 4.4).  For the control, an increasing trend of IGF-1 expression occurred over the 8 
days (3.5 fold increase), but the 10 and 50 ng/mL IGF-1 samples maintained a similar 
level of IGF-1 expression.  At day 1, the 100 ng/mL group had a significantly higher 
level of IGF-1 expression compared to the rest of the samples (p < 0.01).  By day 4, the 




by day 8. Towards the end of the study, the level of IGF-1 expression for the control 
group was significantly higher compared to the experimental groups (p < 0.01), which all 
showed similar expression levels. 
During the 8 days, chondrocytes in all sample groups showed a decreasing trend 
of IGF-1R expression (Figure 4.5).  Similar to IGF-1 expression, at day 1 the 100 ng/mL 
IGF-1 case had the highest level of IGF-1R expression compared to the other groups (p < 
0.01).  By day 4, the 0 and 100 ng/mL IGF-1 group had similar levels of expression that 
were lower than the 10 and 50 ng/mL IGF-1 samples (p < 0.01).  However, by day 8 the 
control group had the lowest IGF-1 expression level compared to all the experimental 
cases (p < 0.01) with a 10 fold decrease from day 1.  
The expression of IGFBP-3 showed a decreasing trend for all groups over the 
course of 8 days (Figure 4.6).  The 100 ng/mL IGF-1 induced group expressed IGFBP-3 
at a higher level compared to the other cases at day 1 (p < 0.01), which also was seen for 
both the IGF-1 and IGF-1R expression. However, by day 4 the IGFBP-3 expression 
levels were not significantly different amongst all the groups (p < 0.01). At day 8, the 0 
and 10 ng/mL IGF-1 groups had similar levels of expression to each other. These groups 
express higher levels of IGFBP-3 expression compared to the 50 and 100 ng/mL IGF-1 
groups (p < 0.01). 
4.3.3 mRNA Expression of Phenotypic Matrix Proteins 
Type II collagen expression occurred for all samples during the 8 day study 
(Figure 4.7).  Almost all of the groups had similar levels of type II collagen expression at 
day 1.  By day 4, type II collagen expression was lowest for the 0 and 100 ng/mL IGF-1 




8 the control samples experienced the lowest level of type II collagen expression with an 
11 fold decrease from day 1 compared to the experimental groups. 
All samples showed an increasing trend of type I collagen expression (Figure 4.8).  
At day 1, the 100 ng/mL IGF-1 group had the highest type I collagen expression level (p 
< 0.01) compared to the other samples.  By day 4, the control group had a greater 
expression of type I collagen (p < 0.01).  The control group continued to experience an 
increase in type I collagen expression, with a 214 fold increase from day 1 to 8 and with 
the highest level of type I collagen occurring at day 8 compared to the experimental cases 
(p < 0.01). 
4.3.4 IGF-1 and Type II Collagen Protein Expression 
The synthesis of IGF-1 and type II collagen proteins by chondrocytes 
encapsulated in alginate hydrogels with and without IGF-1 delivery was determined by 
immunohistochemistry for each protein.  Results indicate that all proteins were being 
synthesized over the course of 8 day study with the highest staining intensity occurring at 
day 8.  For the IGF-1 proteins, staining occurred closely around the chondrocytes for all 
groups at day 1 as seen in the representative image in Figure 4.9a.  In Figures 4.9b-d, 
IGF-1 can be seen in a larger area for all the sample groups at day 8, which all had 
similar staining intensities.  Additionally, similar staining characteristics can be seen for 
type II collagen over the course of the study (Figure 4.10).  For type II collagen staining 
at day 1, the area of staining was concentrated around the chondrocytes (Figure 4.10a) 





The maintenance of chondrocyte phenotype within a three dimensional hydrogel 
has been well established. Previous studies indicate that endogenous expression of IGF-1 
occurs in chondrocytes embedded in alginate hydrogels, but there is little information for 
expression of IGF-1 signaling molecules. To the best of our knowledge, this is the first 
reported study that investigates how exogenous delivery of IGF-1 to chondrocytes, still 
embedded in alginate, affects endogenous expression of IGF-1 signaling molecules.  By 
varying IGF-1 delivery we were able to address the following two major objectives: (1) 
effect of exogenous IGF-1 on endogenous IGF-1 signaling molecules and (2) effect of 
exogenous IGF-1 on chondrocyte phenotypic expression. 
The physical characteristics of the construct were visibly altered during the 8 day 
study. Safranin-O/Fast Green stained images indicate clusters are protruding out of the 
bead (Figure 4.2). These clusters appear to consist of chondrocytes and matrix proteins, 
including proteoglycans, glycosaminoglycans and type II collagen (Figure 4.10). 
Previous studies have indicated that the clusters may consist of pericellular matrices.[230, 
234, 256] These matrices appear to be more prevalent as the IGF-1 delivery concentration 
increases. Cluster formation indicates that the number of chondrocytes, the amount of 
matrix proteins, or both increased during the 8 day study. An increase in DNA content 
did occur for all groups from day 1 to day 8 (Figure 4.3). However, as similar DNA 
levels at each time point were observed for most groups, the results indicate that IGF-1 
has a limited effect on chondrocyte proliferation. Additionally, sample dry weight 
increased significantly by day 8 (Figure 4.1).  Thus it appears that the increase in cluster 




apparent for all groups by day 8, there appears to be less matrix proteins in the control 
group (Figures 4.2 and 4.10). 
The spatial dependence of cluster formation, with fewer clusters in the bead’s 
interior and more clusters along the bead’s periphery, also indicates that IGF-1 transport 
may play a role in this system.  The diffusion coefficient for molecules with molecular 
weights similar to IGF-1 in hydrogels has an order of magnitude of approximately 10-6 
cm2/s, and thus can diffuse through the matrix.[257-259]  However, the concentration of 
clusters around the periphery of the bead indicates that exogenous signal consumption 
may be the critical parameter, where chondrocytes at the periphery consume exogenous 
IGF-1 so that interior chondrocytes see a lower concentration of the signaling molecule.  
Indeed, previous work has found that adipose derived stem cells entrapped in alginate can 
alter diffusion coefficients of dextran (3 kDa) by up to two-fold when culturing with 
chondrogenic media.[259]  However, a more complete study of transport effects is 
necessary in order to fully understand this phenomenon in our experiment. 
For chondrocytes embedded in alginate, it is evident exogenous IGF-1 delivery 
affects endogenous IGF-1 expression during a period of 8 days.  Without exogenous IGF-
1 delivery, IGF-1 expression levels increased throughout the study (Figure 4.4).  This 
result was expected, as chondrocytes attempt to overcome the lack of the IGF-1 signal by 
increasing their endogenous expression of the signal.  (Please note that the use of fetal 
bovine serum in the culture media likely provides some basal level of IGF-1 to all 
groups.)  However, in the presence of excess exogenous IGF-1, regardless of 
concentration, chondrocytes had dramatically lower IGF-1 mRNA expression (Figure 




the 100 ng/mL group had expression level fluctuations from day 1 to day 8 of the study.  
This response may indicate that high levels of IGF-1 delivery induce a time lag for 
reaching equilibrium expression levels. These qRT-PCR measurement of IGF-1 mRNA 
levels is qualitatively supported by immunohistochemistry observation of IGF-1 protein 
levels as demonstrated by Figure 4.9, where the control groups is associated with high 
levels of IGF-1 staining.  Therefore, we conclude that the delivery of high concentrations 
of IGF-1 proteins will induce chondrocytes to decrease their endogenous expression of 
IGF-1. 
The overall trend observed in IGF-1 expression is largely reflected by the IGF-1R 
expression.  At day 1 and 4, differences in IGF-1R expression are observed between the 
experimental and control groups (Figure 4.5).  The fluctuations seen at day 1 and day 4, 
possibly reflects a sluggish response in gene expression patterns by embedded 
chondrocytes. This slow response may be concentration dependent, where the delivery of 
high concentrations of IGF-1 are associated with longer times for chondrocyte gene 
expression patterns to change and perhaps to also reach equilibrium.  However, by 
observing IGF-1R expression up to day 8, the results indicate that in the presence of 
excess IGF-1, chondrocytes express higher levels of IGF-1R. This could allow for an 
increase in the amount of available IGF-1R or, alternatively, a greater turnover rate of 
IGF-1R so as to potentially bind more available IGF-1. 
While distinctive differences in IGF-1 and IGF-1R expression were observed 
between experimental and control groups by day 8, IGFBP-3 expression did not appear to 
be largely influenced by IGF-1 delivery (Figure 4.6).  Over the course of the study a 




because cartilage explants that are exposed to 100 ng/mL IGF-1 have been found to show 
an increase in IGFBP-3.[245, 246] However, the consistently low IGFBP-3 expression 
seen in this study indicates that exogenous IGF-1 has a limited impact on IGFBP-3 
expression for alginate embedded chondrocytes. Therefore, since (1) IGF-1 delivery 
downregulates IGF-1 expression while upregulating IGF-1R expression and (2) IGF-1 
delivery does not significantly alter IGFBP-3 expression, we hypothesize that IGF-1 
signaling is mostly regulated by IGF-1R expression. 
The impact of exogenous IGF-1 delivery is not limited to the expression of IGF-1 
signaling molecules, but also has profound effects upon chondrocyte phenotype.  Type II 
collagen mRNA expression (Figure 4.7) is strikingly similar to IGF-1R mRNA 
expression (Figure 4.5).  Furthermore, the expression of type I collagen (Figure 4.8), a 
marker of chondrocyte dedifferentiation, is almost entirely in opposition to type II 
collagen and IGF-1R expression.  These patterns generally support the hypothesis that 
IGF-1R is a key factor in regulating IGF-1 signaling.  Though in our studies expression 
levels up to day 8 were our primary focus, we propose that the upregulation of type II 
collagen expression and low type I collagen expression in response to IGF-1 delivery 
should continue beyond 8 days, as demonstrated in previous studies.[260, 261] 
The results presented here confirm the significant role of IGF-1 in chondrocyte 
function that has been previously demonstrated.  However, here we characterize the 
effects of IGF-1 delivery to a 3D system relevant to many tissue engineering strategies 
under development.  Interestingly, the results also show that exogenous IGF-1 impacts 
the endogenous expression of IGF-1 and IGF-1R, but not IGFBP-3.  One would suspect 




this would then stabilize the IGF-1.  Since IGFBP-3 expression did not change, but IGF-1 
and IGF-1R expression did become altered, we hypothesize that the uptake of exogenous 
IGF-1 is controlled mainly by IGF-1R expression, within the range of exogenous IGF-1 
delivery and time length studied. 
As many tissue engineering strategies suggest a longer period of in vitro culture 
before implantation, it is important to consider time points beyond 8 days.  Since the 
mRNA expression between the control group and experimental cases for IGF-1, IGF-1R, 
type II collagen and type I collagen were significantly different at day 8, we speculate 
that the expression patterns observed here will continue at longer time points, but future 
studies are certainly required for confirmation. Though, in this particular study we did not 
observe beyond 8 days, the results indicate that within the 8 days there are notable 
differences in endogenous expression levels of IGF-1 signaling molecules as well as 
phenotypic expression between the control versus experimental groups. Therefore, from 
these observations, we propose that developing engineered tissues relies on critically 
inspecting endogenous expression of signaling molecules by cells embedded within a 
scaffold that are delivered with exogenous signals. 
4.5 Conclusions 
Here we observe for the first time, the expression of IGF-1 signaling molecules by 
chondrocytes embedded in an alginate hydrogel matrix.  The results indicate that IGF-1 
and IGF-1R expression, as well as proper chondrocyte phenotypic function, are greatly 
affected by IGF-1 delivery, although IGFBP-3 expression is largely unaffected by IGF-1 
delivery.  Therefore, the results indicate that hydrogel embedded chondrocytes, exposed 




through IGF-1R expression.  Furthermore these findings demonstrate the profound effect 
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Figure 4.1.  The dry weight of alginate beads for the 0, 10, 50, and 100 ng/mL IGF-1 

















Figure 4.2.  Safranin-O/Fast Green stained sections at (a) day 1 for 50 ng/mL IGF-1 
group, (b) day 8 for 0 ng/mL IGF-1 group, (c) day 8 for 10 ng/mL IGF-1 group, (d) day 8 
for 50 ng/mL IGF-1 group, and (e) day 8 for 100 ng/mL IGF-1 group. Alginate beads are 
a bright orange color, while the matrix proteins are shown with an arrow (light orange 
hue), and chondrocytes are shown with double arrows (gray hue).  Scale bars are located 
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Figure 4.3.  DNA content per bead for all sample groups over the course of 8 days.  
There is an increasing trend of DNA for all groups during the length of the study. 
However, no differences in DNA levels were seen between all the groups at each time 
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Figure 4.4.  IGF-1 mRNA expression for all sample groups over 8 days.  Results indicate 
that at day 8, IGF-1 induced samples had lower levels of gene expression compared to the 
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Figure 4.5.  IGF-1R mRNA expression for all sample groups over 8 days.  An increased 
level of expression occurred in the experiment groups versus the control group at day 8.  
The means and standard deviations are reported (n = 3,  indicates p < 0.01). The labels ‡ 
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Figure 4.6.  IGFBP-3 mRNA expression for all sample groups over 8 days.  A decrease 
in IGFBP-3 expression occurred for all groups by 8 days.  The means and standard 
deviations are reported (n = 3,  indicates p < 0.01).  The labels ‡ and # indicate no 
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Figure 4.7.  Type II collagen mRNA expression for all sample groups over 8 days.  
Chondrocytes sustained their expression for the experimental groups by day 8, while a 
decrease in expression occurred for the control group. The means and standard deviations 
are reported (n = 3,  indicates p < 0.01). The labels ‡ and # indicate no statistical 
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Figure 4.8.  Type I collagen mRNA expression for all sample groups over 8 days.  A 
higher level of expression occurred in the control group versus the experimental groups 
by the day 8 time point.  The means and standard deviations are reported (n = 3,  






















Figure 4.9.  IGF-1 immunohistochemistry staining at (a) day 1 for 100 ng/mL IGF-1 
group, (b) day 8 for 0 ng/mL IGF-1 group, (c) day 8 for 10 ng/mL IGF-1 group, (d) day 8 
for 50 ng/mL IGF-1 group, (e) day 8 for 100 ng/mL IGF-1 group, and (f) a negative 
staining control.  The clusters stained with greater intensity at day 8 compared to the 






















Figure 4.10.  Type II collagen immunohistochemistry staining for (a) day 1 for 100 
ng/mL IGF-1 group, (b) day 8 for 0 ng/mL IGF-1 group, (c) day 8 for 10 ng/mL IGF-1 
group, (d) day 8 for 50 ng/mL IGF-1 group, (e) day 8 for 100 ng/mL IGF-1 group, and (f) 
a negative staining control.  The presence of type II collagen seems to be greater at day 8 
for the groups that received exogenous IGF-1.  Scale bars are located on the bottom right 




5 Hyaluronic Acid Interferes with IGF-1 Signaling Among 
Alginate Embedded Chondrocytes 
5.1 Introduction 
In order to maintain healthy cartilage, a balance between the chondrocytes and 
their environment is required.  However it is difficult to investigate all the interactions 
occurring in cartilage simultaneously.  Therefore, most tissue engineers examine a few 
variables at a time to truly understand the intricate details.  Growth factors for example 
have shown their importance in tissue regeneration [11, 15, 247, 262, 263].  As 
previously mentioned, insulin-like growth factor-1 (IGF-1) is an essential anabolic 
growth factor that promotes matrix production as well as chondrocyte proliferation in 
cartilage explants [2, 236, 237, 264, 265]. 
Alterations in construct design, such as seeding density, scaffold porosity, 
scaffold composition, and mechanical stimulation are just a few variables that have been 
found to impact chondrocyte function [253, 266-271].  Our previous studies investigated 
the change in expression of IGF-1 signaling molecules by embedded chondrocytes when 
the construct environment is altered, such as cell density, alginate hydrogel concentration, 
and exogenous IGF-1 delivery.  We found that at a high cell density and alginate 
concentration, type II collagen and IGF-1 expression were both enhanced [253].  
Delivery of exogenous IGF-1 led to chondrocyte expression of IGF-1 to decrease, IGF-
1R to increase, and IGFBP-3 to become unchanged [272]. It was interesting to see that 
varying the IGF-1 concentration (0 - 100 ng/mL) did not impact differences in expression 




Here, we have investigated how endogenous IGF-1 expression changed when 
chondrocytes are introduced to hyaluronic acid (hyaluronan, HA), which is a large 
molecular weight glycosaminoglycan that is readily found in cartilage.  Its molecular 
weight in the articular cartilage region can range from approximately 500,000 to 
7,000,000 [273-275].  The major role of HA is to act as a base for aggrecan molecules, 
ultimately forming into proteoglycans with a highly negative charge, allowing cartilage to 
have viscoelastic properties when under biomechanical pressures [275].  Chondrocytes 
interact with HA by the receptor CD44 to maintain an organized extracellular matrix, 
which is necessary for cartilage homeostasis [276, 277]. 
There has been investigation of chondrocyte function in the presence of 
hyaluronic acid with varying results.  Embedded chondrocytes in alginate/HA hydrogels 
or polylactate and polyglucuronic (PLGA)/HA scaffolds had an increase in proliferation, 
glycosaminoglycan, and hydroxyproline content compared to just alginate or PLGA 
alone [278, 279].  However, when hyaluronic acid was added to chondrocytes 
encapsulated in either alginate or a collagen gel with PLGA acid mesh, chondrocytes 
proliferation did not fluctuate [280, 281].  For chondrocytes in alginate/HA hydrogels 
with the presence of dynamic mechanical stimulation it showed the hyaluronic acid 
increased type I collagen expression [280].  In other studies, hyaluronic acid hydrogels 
with mechanical loading showed enhancement of type II collagen expression while 
maintaining low levels of type I collagen expression [282].  Additionally, chondrocytes in 
collagen/PLGA meshes had a decrease in expression of aggrecan and type II collagen as 
the hyaluronic acid concentration increased (0, 10, and 100 mg/L) [281].  To our 




directly affected by chondrocytes that interact with hyaluronic acid in a 3-D system.  
Therefore, the objectives of this work are to examine the (1) expression of IGF-1 
signaling molecules by chondrocytes in the presence of hyaluronic acid and IGF-1, and 
(2) to determine if exogenous IGF-1 and hyaluronic acid enhances phenotypic matrix 
expression. 
5.2 Materials and Methods 
5.2.1 Materials 
The Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 Ham 
(DMEM/F12) media (with and without phenol red), penicillin/streptomycin, sodium 
pyruvate, Quant-iT PicoGreen dsDNA Assay kit, HISTOSTAIN®-SP Kit and Liquid 
DAB Substrate Kit were obtained from Invitrogen (Carlsbad, CA).  The ascorbic-2-
phosphate, bovine serum albumin, sodium bicarbonate, alginic acid sodium salt from 
brown algae, hyaluronic acid sodium salt from Streptococcus equi (53747) and HEPES 
were purchased from Sigma-Aldrich (St. Louis, MO).  Collagenase P was purchased 
from Roche (Basel, Switzerland).  The human insulin-like growth factor-1 (hIGF-1), anti-
hIGF-1 (goat IgG, AF-291-NA), and IGF-1 Elisa Kit were obtained from R&D Systems 
(Minneapolis, MN).  The anti-CD44 (rat monoclonal, ab19622), anti-type II collagen 
(rabbit polyclonal, ab300), anti-type I collagen (mouse monoclonal, ab6308), and HRP 
conjugated goat secondary antibody (IgG, ab6885) were purchased from Abcam 
(Cambridge, MA).  The RNeasy Plus Mini Kit and DNeasy Blood and Tissue Kit were 
obtained from Qiagen (Valencia, CA).  The Citrisolv Hybrid, Paraplast X-tra paraffin, 
Fast Green stain, and Permount were purchased from Fisher Scientific (Pittsburgh, PA).  




Kit, Universal Master Mix, oligonucleotide primers, and Taqman probes used for RT-
PCR were purchased from Applied Biosystems (Foster City, CA).  The 12 mm diameter 
polyester membrane transwell inserts with 3 μm pore size were obtained from Corning 
Incorporation (Corning, NY). 
5.2.2 Methods 
5.2.2.1 Cartilage Extraction and Chondrocyte Isolation 
Cartilage was removed from the metatarsal phanlangeal joint of calves (20-22 
weeks old). The slices were washed in DMEM/F12 media, which contained the following 
additives: 50 μg/mL ascorbic-2-phosphate, 1 mg/mL bovine serum albumin, 1.2 mg/mL 
sodium bicarbonate, 0.1% penicillin/streptomycin, and 0.1% sodium pyruvate. The 
cartilage was incubated overnight in 0.2% collagenase P at 37oC and then filtered 
through a 40 µm nylon mesh to isolate primary chondrocytes. 
 
5.2.2.2 Chondrocyte Encapsulation and Culture 
Alginate was chosen to be the base polymer at a 2.0% w/v concentration for this 
study. Four different amounts of hyaluronic acid were added to alginate to have the 
following concentrations: 0, 0.05, 0.50, and 5.00 mg/mL. The hydrogel solution was 
prepared by mixing and heating alginic acid, hyaluronic acid, 0.15 M sodium chloride, 
and 0.025 M HEPES into deionized water (pH 7.4). The final solution was sterilized 
through a 0.22 μm syringe filter and then mixed with chondrocytes to obtain a cell 
density of 100,000 cells/bead.  This solution was injected through an 18 gauge syringe 
into a 100 mM calcium chloride solution for 15 minutes and then rinsed in DMEM/F12 
for 15 minutes. Afterwards, 5 beads were transferred into each well of a 6-well plate and 




changed on day 3 with DMEM/F12 media, 10% FBS, and 100 ng/mL hIGF-1.  Human 
IGF-1 was used because it has a similar homology to bovine IGF-1 [255]. The media and 
IGF-1 were changed daily. Chondrocytes were isolated from 5 alginate/HA beads for 
analysis at day 1, 4, and 8 by the addition of 4 mL of 0.1M ethylenediaminetetraacetic 
acid (EDTA) for 30 minutes at 37oC. A cell pellet was formed by centrifugation and then 
resuspended in PBS and split for RNA and DNA isolation. 
 
5.2.2.3 RNA Isolation 
Total RNA was isolated from chondrocytes by following the instructions provided 
in the RNeasy Plus Mini Kit. Total RNA was eluted into 30 μL of RNase free water and 
detected using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). 
 
5.2.2.4 DNA Isolation and Quantification 
Total DNA was isolated from chondrocytes using a DNeasy Blood and Tissue Kit 
by following the details in the manual instructions. Total DNA was eluted in 400 μL of 
an AE buffer and then incubated with PicoGreen supplied from a Quant-iT PicoGreen 
dsDNA Assay kit. The samples were excited at 480 nm and evaluated at an emission of 
520 nm using a fluorescence microplate reader (Molecular Devices SpectraMax M5, 
Sunnyvale, CA). A standard curve was prepared from a known concentration of DNA 






All samples were collected and fixed in 4% paraformaldehyde and 0.1 M sodium 
cacodylate buffer containing 10 mM CaCl2 (pH 7.4) for 24 hours at 4
oC. The beads were 
washed with 0.1 M sodium cacodylate buffer with 10 mM CaCl2 (pH 7.4) for 24 hours at 
room temperature. Afterwards, the beads were dehydrated in a series of ethanol 
concentrations (40-100%) with a final Citrisolv Hybrid wash. The samples were 
embedded in Paraplast X-tra paraffin and cut into 4 µm thickness sections, which were 
placed onto charged microscope slides and kept at 4oC until staining. 
 
5.2.2.6 Histochemical Staining 
Sections were oven dried for 2 hours at 60oC, deparaffinized in Citrisolv Hybrid 
two times for 3 minutes, rehydrated in 100% and 95% ethanol for 1 minute each, and 
rinsed in distilled water. Sections were stained with Safranin-O (0.1%) and counter 
stained with Fast Green (0.001%). 
 
5.2.2.7 Immunohistochemistry 
Sections were prepared as previously described [272].  The following antibodies 
were used to stains for the presence of CD44, IGF-1, type II collagen, and type I 
collagen. The primary antibodies are:  anti-CD44, anti-hIGF-1, anti-type II collagen, and 
anti-type I collagen.  The antibodies for CD44 and type I collagen were diluted 1:100.  
The antibodies for IGF-1 and type II collagen were diluted 1:200.  A HISTOSTAIN®-SP 
Kit was used to reveal the presence of CD44, type II collagen, and type I collagen by 
using a horseradish peroxidase (HRP)-strepavidin-biotin system. This complex formation 




1, a HRP conjugated secondary goat antibody was used at a dilution of 500 times and 
detected by a histochemical substrate (Liquid DAB Substrate Kit). All samples were 
counterstained with hematoxylin, dehydrated in 95% and 100% ethanol twice for 1 
minute each, cleared in Citrisolv Hybrid twice for 1 minute, and coverslipped using 
Permount.  To show non-specific staining, samples were not incubated with the primary 
antibody and then incubated with the secondary antibody for each protein (negative 
staining control). 
 
5.2.2.8 Quantitative Reverse Transcriptase-Polymerase Chain Reaction 
(qRT-PCR) 
 
Isolated mRNA was reverse transcribed using a cDNA Archive Kit. Quantitative 
RT-PCR was performed by combining the cDNA solution with a Universal Master Mix, 
as well as oligonucleotide primers and probes that were created for the genes of interest 
(IGF-1, IGF-1R, IGFBP-3, CD44, type II collagen, and type I collagen) and the 
endogenous gene control (glyceraldehyde 3 phosphate dehydrogenase, GAPDH).  The 
same primer and probes for IGF-1, IGF-1R, IGFBP-3, type II collagen, type I collagen, 
and GAPDH were used from previous work [253, 272].  The sequences for the forward 
primer, reverse primer, and probe for CD44 are 5’ CGGGTTCATAGAAGGGCATGT 
3’, 5’ TGTTCGCAGCACAGATGGA 3’, and 5’ ATTCCCCGGATCCAC 3’.  The 
reaction was conducted on an ABI Prism 7000 sequence detector (Applied Biosystems), 
using thermal conditions of 2 minutes at 50oC, 30 minutes at 60oC, 5 minutes at 95oC, 
and 40 cycles of 20 seconds at 94oC and 1 minutes at 62oC.  The expression for each gene 
was analyzed for all the groups in the study using a relative comparative method, which 




expression sample set was analyzed to the 0 mg/mL HA sample at day 1.  This calibrator 
was chosen to represent the gene expressions data appropriately. 
5.2.2.9 Release of IGF-1 in Alginate/HA Hydrogels 
Cell free 0, 0.05, 0.50, and 5.00 mg/mL HA alginate solutions (200 μL) were each 
injected into 12 mm diameter size transwell inserts.  The solutions were immersed in a 
100 mM solution of calcium chloride for 30 minutes.  The alginate/HA gel was rinsed in 
phenol free DMEM/F-12 with 15mM HEPES, 50 μg/mL ascorbic-2-phosphate, and 1 
mg/mL BSA for 30 minutes.  Finally, the gel inserts were immersed in the same media 
used for rinsing and equilibrated for 3 days in a cell culture incubator.  After 3 days, the 
inserts were put into 12-well plates containing 2 mL of the same media used earlier along 
with 2 μg of hIGF-1.  Fresh media (450 μL) was placed on top of the gel.  At the 
following time points, 100 μL of the solution on top of the gels was removed and placed 
in -20 oC freezer until analysis: 0, 2, 4, 6, 8, 10, 12, 24, and 48 hours.  The removed 
media was replaced with fresh 100 μL DMEM/F-12.  Samples were tested for hIGF-1 
content by a hIGF-1 Elisa Kit. 
5.2.2.10 Statistical Analysis 
Data from all studies were analyzed using ANOVA and Tukey’s multiple-
comparison test. The means and standard deviations are reported in each figure. 
5.3 Results 
5.3.1 Hyaluronic Acid Entanglement in Alginate 
Proliferation was monitored by chondrocytes embedded in the alginate/HA beads.  




levels of DNA were not significantly different amongst the groups at day 1, 4, or 8.  
However, there was an increasing trend in DNA from day 1 to 8 for all the groups. 
To confirm that hyaluronic acid was being retained in the alginate beads, they 
were weighed as well as stained with Safranin-O and Fast Green.  The water content of 
the alginate/HA beads for all the groups were approximately 96% throughout the whole 
experiment.  The incorporation of hyaluronic acid increased the bead dry weight (Figure 
5.2).  All the groups were significantly different from each other (p < 0.01) except for the 
0 and 0.05 mg/mL HA groups at each time point.  Additionally, the groups individually 
maintained steady weights during the time course of the experiment. 
The Safranin-O and Fast Green stained histology sections showed that 
chondrocytes were thoroughly dispersed in the alginate/HA beads, which can be seen by 
their gray stained nuclei (Figure 5.3).  Safranin-O/Fast Green stain turns alginate into an 
intense orange color, while making the proteoglycans and glycosaminoglycans appear as 
a fainter orange hue [261].  Seen in Figure 5.3 at day 1, the orange stain becomes lighter 
as the incorporation of hyaluronic acid increases.  By day 8, the orange color became 
darker for the alginate/HA beads.  Clustering of chondrocytes was observed around the 
circumference for all the alginate/HA beads (not shown), which was similar in 
appearance to previous work [272]. 
5.3.2 CD44 mRNA Expression 
In order to ensure that hyaluronic acid was interacting with the embedded 
chondrocytes in the alginate/HA beads, CD44 mRNA expression was analyzed (Figure 
5.4).  At day 1, all the chondrocytes expressed CD44 at similar levels.  By day 4, only the 




continued 2 fold increase in CD44 expression was also observed by the chondrocytes at 
day 8. 
5.3.3 Endogenous mRNA Expression of IGF-1 Signaling Molecules 
The embedded chondrocytes in all the alginate/HA beads expressed IGF-1 
throughout the 8 day study (Figure 5.5).  The 0 mg/mL HA case had a 6 fold increase in 
expression of IGF-1, while the 0.05, 0.50, and 5.00 mg/mL HA groups all had a 2 fold 
increase from day 1 to 4.  The 0 mg/mL HA group had the highest level of IGF-1 
expression compared to the other groups at day 4 (p < 0.01).  From day 4 to 8, the 
chondrocytes embedded in the 0 mg/mL HA beads maintained their level of IGF-1 
expression.  A 5 fold increase of expression was seen by the 0.05 mg/mL HA beads, 
while the other two groups, 0.50 and 5.00 mg/mL HA, both had a 2 fold increase in IGF-
1 expression from day 4 to 8.  At day 8, the 0.05 mg/mL HA group had the highest level 
of IGF-1 expression compared to the other groups (p < 0.01).  The 0.50 mg/mL HA case 
had higher IGF-1 expression (p < 0.01) than the 0 and 5.00 mg/mL HA samples, which 
did not have significant differences in expression levels. 
IGF-1R expression was observed from all the groups during the 8 day period 
(Figure 5.6).   At day 1, the expression levels for all the alginate/HA groups did not differ 
significantly.  Throughout the experiment, the only group that experienced fluctuations of 
IGF-1R expression was the 0 mg/mL HA group.  There was a 3 fold increase in IGF-1R 
expression from day 1 to 4 and then a 3.5 fold decrease in IGF-1R expression from day 4 
to 8.  At day 4 and 8, the 0 mg/mL HA group had expression levels that were 




During the 8 day study, the expression of IGFBP-3 decreased for all sample 
groups (Figure 5.7).  The 0.05 mg/mL HA group had the highest level of IGFBP-3 
expression compared to the other cases at day 1 (p < 0.01).  However, by day 4 the 
expression levels had more variance among the groups.  The 0 mg/mL and 0.50 mg/mL 
HA group both had a 1.5 fold increase in IGFBP-3 expression.  The other two groups, 
0.05 mg/mL and 5.00 mg/mL HA, had a decrease in expression with a 6.6 and 0.6 fold 
change, respectively.  The 0 mg/mL HA group had the highest expression level at day 4 
followed by the 0.50 mg/mL HA case (p < 0.01).  There was no difference in IGFBP-3 
expression between the 0.05 and 5.00 mg/mL HA group.  By day 8, all the groups 
expressed equal levels of IGFBP-3. 
5.3.4 mRNA Expression of Phenotypic Matrix Proteins 
All the chondrocytes embedded in the alginate/HA beads expressed type II 
collagen during the 8 day study (Figure 5.8).  The 0 and 5.00 mg/mL HA group at day 1 
had similar levels of type II collagen expression.  Additionally, the 0.05 and 0.50 mg/mL 
HA group were not significantly different but had higher type II collagen expression 
levels compare to the 0 and 5.00 mg/mL HA cases (p < 0.01).  Similar trends were found 
at day 4 for all the groups (p < 0.01).  The 0, 0.05, and 0.50 mg/mL HA groups decreased 
in type II collagen expression by 0.8, 1.5, and 1.5 fold difference respectively from day 1 
to 4.  The 5.00 mg/mL HA group was the only case that did not change in expression 
level.  From day 4 to 8, the type II collagen expression levels decreased for all the groups.  
The most change was experienced by the 0 mg/mL HA group with a 5 fold difference, 




mg/mL HA groups had similar levels of expression with fold changes of 2.7, 3.7, and 1.5 
from day 4 to 8, respectively. 
Type I collagen was also expressed by all the samples throughout the study 
(Figure 5.9).  From day 1 to 8, all the groups significantly increased in type I collagen 
expression.  The expression levels were similar amongst the groups at day 1.  
Additionally, there were no significant differences in type I collagen expression between 
the samples at day 4.  By day 8, the 0 mg/mL HA group had a 34 fold increase in type I 
collagen, which was the lowest compared to alginate beads that contained hyaluronic acid 
(p < 0.01).  The largest increase in type I collagen expression was by the 0.05 mg/mL HA 
group with a 78 fold change.  Type I collagen expression was increased by 40 fold for the 
0.5 mg/mL HA group and by a 52 fold for the 5 mg/mL HA group. 
5.3.5 CD44, IGF-1, Type II Collagen, and Type I Collagen Protein 
Expression 
 
Immunohistochemistry was performed for all the groups at each time point in 
order to confirm that the embedded chondrocytes were synthesizing the proteins of 
interest.  All the proteins increased in abundance by day 8 and were located primarily 
surrounding the chondrocyte clusters (Figure 5.10).  CD44 stained strongly within the 
chondrocyte clusters, while IGF-1 was found to be present outside the clusters as well.  
Type II collagen staining seemed to be greater than type I collagen staining for all the 
groups. 
5.3.6 Release of IGF-1 in Alginate/HA Hydrogels 
All the alginate/HA groups released less than 2% of the initial total IGF-1 amount 




ng more IGF-1 compared to the 5.00 mg/mL HA case.  At 24 and 48 hours the 5.00 
mg/mL HA group had significantly lower amounts of IGF-1 released compared to all the 
other cases (p < 0.01).  Steady state release of IGF-1 was achieved by 48 hours for all the 
groups. 
5.4 Discussion 
We have shown in earlier works that in a 3-D alginate hydrogel system, delivering 
exogenous IGF-1 to the embedded chondrocytes alters the endogenous expression of 
upstream IGF-1 signaling molecules, such as IGF-1 and IGF-1R [272].  We were 
therefore interested to investigate how incorporating hyaluronic acid, a chondrocyte 
adhesion moiety, within alginate hydrogels would affect the endogenous expression of 
IGF-1 signaling molecules.  Thus, in the present study, we varied the amount of 
hyaluronic acid in alginate to investigate the following objectives: (1) effect of hyaluronic 
acid on endogenous IGF-1, IGF-1R, and IGFBP-3 and (2) effect of hyaluronic acid on 
chondrocyte phenotypic expression. 
As alginate hydrogels have a high porosity, there is a concern that hyaluronic acid 
may diffuse out of the alginate beads.  Previous work shows that at 2.4% w/v alginate, 
hyaluronic acid has a higher retention ability compared to lower alginate concentrations 
[283].  Additionally, the incorporation of chondrocytes in alginate beads also decreases 
the potential release of hyaluronic acid [280, 283].  In order to confirm that in this 
system, hyaluronic acid did not leach out of the alginate beads, we measured bead dry 
weight (Figure 5.2) and stained with Safranin-O/Fast Green (Figure 5.3).  The dry 
weights of the beads at all time points was higher for the groups that contained 0.50 and 




similar levels of DNA content at each time point and the alginate concentration was the 
same in the experiment, the higher dry weights imply that the alginate beads retained HA.  
This data is consistent with the Safranin-O/Fast Green stained bead images which show 
proteoglycans and glycosaminoglycans in an orange hue but in contrast to alginate, it is a 
much lighter orange shade.  At day 1, it can be seen that as the HA content increases the 
stain becomes a lighter orange color, indicating that the free HA is entangled in the 
alginate beads.  However, by day 8 all the images become a darker orange hue, indicating 
that there is some loss of HA from the beads as the study progressed.  The loss of HA is 
also indicated by the lack of change in dry weights of the beads from day 1 to day 8 for 
all the groups.  In this experiment, chondrocytes proliferated and formed matrix protein 
clusters on the bead periphery.  These cluster formations can increase the dry weights but 
since the dry weights did not fluctuate, this indicates that some HA could have leached 
out of the bead. 
The mRNA expression of CD44, further confirmed that HA was present in the 
beads (Figure 5.4).  Chondrocytes with and without free HA produced CD44 proteins as 
seen by immunohistochemical staining (Figure 5.10).  However, variations were seen in 
chondrocyte CD44 mRNA expression.  At day 1 all the groups expressed CD44 but by 
day 4 only the groups that contained HA expressed high levels of CD44.  This trend 
continued till day 8, indicating that HA was still present in the beads and additionally the 
chondrocytes are interacting with HA.  It was interesting to see that despite the varying 
concentrations of HA in the construct, chondrocytes expressed similar levels of CD44 
mRNA throughout the 8 day study.  A continuous expression of CD44 is expected since 




The 0.05 mg/mL HA concentration seems to be enough to allow for chondrocyte 
adherence to hyaluronic acid.  When hyaluronic acid attaches onto CD44, chondrocytes 
have the ability to internalize HA via endocytosis [277].  However, in order to 
continually attach to the free hyaluronic acid, chondrocytes must continue to express 
CD44.  Therefore, this might be why we see a constant steady level of CD44 expression.  
This steady state level could possibly be a saturating point for CD44 expression and it 
seems to be reached by chondrocytes surrounded with a HA concentration of 0.05 
mg/mL.  We speculate that a decrease in CD44 expression may be observed if HA 
concentration is further lowered.   
We have found in earlier experiments that incubating chondrocytes with 
exogenous IGF-1 depresses endogenous expression of IGF-1 [272].  In this particular 
study, the objective was to determine how the incorporation of hyaluronic acid affects 
chondrocyte interaction with delivered IGF-1.  Our data showed that hyaluronic acid 
influenced IGF-1 expression by day 8 (Figure 5.5).  The synthesis of IGF-1 proteins was 
confirmed by immunohistochemistry for all the groups at day 8 (Figure 5.10).  However, 
the IGF-1 mRNA expression decreased as higher amounts of hyaluronic acid was added 
to the alginate beads.  Since the amount of IGF-1 retentation is similar for the 0, 0.05, and 
0.50 mg/mL HA groups, it seems that hyaluronic acid interaction with the chondrocytes 
can increase the mRNA expression of IGF-1.  Interestingly, the 5.00 mg/mL HA group 
had similar IGF-1 expression levels compared to the 0 mg/mL HA group.  In a high HA 
concentration (5.00 mg/mL), IGF-1 becomes entrapped in the hydrogel (Figure 5.11).  A 
similar result was seen in cartilage explants, when exposured to free hyaluronic acid led 




IGF-1 and decrease their need to express endogenous IGF-1.  It seems that once a certain 
dosage of free hyaluronic acid is reached, there is a well concentrated entrapped supply 
of IGF-1 to the chondrocytes.  As a result chondrocytes start to have IGF-1 expression 
levels similar to samples that contain no hyaluronic acid. 
Chondrocyte interaction with IGF-1 is primarily through its own specific receptor, 
IGF-1R [272, 285].  A correlation in IGF-1 expression and IGF-1R expression could then 
be expected.  Since the chondrocytes were incubated with exogenous IGF-1, there should 
be an increase in expression of the receptor for the control group as seen in previous 
studies [272, 285].  While an increase is observed by day 4, which is expected, a decrease 
occurs in IGF-1R expression by day 8 (Figure 5.6).  While this sudden decrease in 
expression is unclear, the fluctuation in expression shows that exogenous IGF-1 is 
affecting the receptor expression.  However, for the groups that have hyaluronic acid, 
there is no change in IGF-1R expression throughout the study.  We speculate that 
hyaluronic acid might have a role in the regulation of IGF-1R in the presence of 
exogenous IGF-1.  While this is the first reported study to investigate IGF-1R expression 
by embedded chondrocytes in the presence of IGF-1 and HA, the interaction of 
hyaluronic acid with IGF-1R can be confirmed by a previous study involving 
chondrocyte treatment with interleukin-1 (IL-1).  Here it was found that when 
chondrocytes were treated with IL-1, the presence of HA actually increased IGF-1R 
protein levels [286].  However, the details of how HA interacts with IGF-1 signaling has 
still yet to be fully understood. 
In regards to IGFBP-3 expression, hyaluronic acid does not seem to have an 




5.7).  This lack of expression further indicates that IGFBP-3 is not a controlling factor for 
intake of exogenous IGF-1 by embedded chondrocytes as found in previous work [272]. 
Chondrocytes continued to express type II collagen, a primary phenotypic marker, 
throughout the study for all the groups (Figure 5.8).  Though there is a decrease in mRNA 
expression from day 1 to 8, the immunohistochemistry stains indicate that type II 
collagen was being highly produced for all the groups at day 8 (Figure 5.10).  Therefore, 
indicating that the chondrocytes are maintaining their phenotype.  Despite the continuous 
expression of type II collagen, there was also expression of type I collagen, indicating a 
fibroblastic phenotype.  The protein expression of type I collagen was less intense than 
type II collagen at day 8 (Figure 5.10).  However, type I collagen mRNA expression 
increased for all the groups throughout the experiment (Figure 5.9).  The expression of 
type I collagen has been found to occur by chondrocytes embedded in 2.0% w/v alginate 
with or without exogenous IGF-1 [272].  However, type I collagen expression is lower 
for chondrocytes when exposed to IGF-1.  In this experiment, hyaluronic acid seems to 
further increase chondrocyte type I collagen expression by day 8 when in contact with 
excess IGF-1.  Even without IGF-1, it has been found that hyaluronic acid increases type 
I collagen expression [282].  This indicates that hyaluronic acid possibly overpowers the 
affect of exogenous IGF-1 by making the chondrocytes retain more of a fibroblastic 
phenotype. 
Incorporation of hyaluronic acid has been shown to affect how exogenous IGF-1 
interacts with embedded chondrocytes in alginate hydrogel.  This is to be expected 
because of the importance that attachment proteins play in articular cartilage function.  




chondrocytes and thus altering embedded chondrocyte IGF-1 expression.  While 
normally IGF-1R expression by chondrocytes would be increased when delivered IGF-1, 
in the presence of hyaluronic acid there is minimal change.  This could indicate a possible 
interaction between hyaluronic acid and IGF-1R.  Hyaluronic acid seemed to have a huge 
influence over the affect of exogenous IGF-1 by chondrocytes because of the increase in 
type I collagen, indicating a more fibroblastic phenotype.   Overall, these results show 
that the expression of upstream IGF-1 signaling molecules by chondrocytes is sensitive 
by the addition of free hyaluronic acid as well as its phenotypic function, especially when 
embedded in a 3-D alginate hydrogel. 
5.5 Conclusions 
From the results we obtained from this study, in the presence of exogenous IGF-1 
we found that hyaluronic acid affects chondrocyte phenotypic function as well as IGF-1 
expression and IGF-1R expression.  Hyaluronic acid has been known to increase 
chondrocyte expression of type I collagen and in this study similar results were observed.  
The concentration of hyaluronic acid within alginate allowed for chondrocyte interaction 
and retention of exogenous IGF-1.  Therefore, HA was shown to control the expression 
of IGF-1 by the embedded chondrocytes.  Additionally, the presence of hyaluronic acid 
might be interacting with IGF-1R and altering the receptor expression despite the 
presence of excess IGF-1.  We further concluded that IGFBP-3 expression is changed 
minimally by the introduction of hyaluronic acid and does not seem to play a vital role in 
IGF-1 signaling for embedded chondrocytes.  From the data collected in this experiment, 
there are potentially some regulatory mechanisms that are shared between the HA and 




Overall, we have shown that it is important to understand how construct properties can 
affect chondrocyte endogenous expression of upstream IGF-1 signaling molecules in 





























Figure 5.1.  Nanogram DNA levels per bead for all sample groups over the experimental 
time course of 8 days.  There is no significant difference in DNA levels among each of 




































Figure 5.2.  The alginate/HA bead dry weights were measured for the following groups 
during the time course of the experiment: 0, 0.05, 0.50, and 5.00 mg/mL HA.  The means 


































































Figure 5.3.  Safranin-O and Fast Green stained sections at day 1 and day 8 for 0 mg/mL 
HA, 0.05 mg/mL HA, 0.50 mg/mL HA, and 5.00 mg/mL HA.  Alginate stains into an 
intense orange color, hyaluronic acid becomes a lighter orange hue, and chondrocytes a 
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Figure 5.4.  CD44 mRNA expression for all sample groups over 8 days.  Chondrocytes 
only expressed CD44 in the groups that contained hyaluronic acid in the alginate beads at 
day 4 and 8.  There was no statistical difference in CD44 expression when there were 
different hyaluronic acid concentrations.  The means and standard deviations are reported 































Figure 5.5.  Chondrocytes in all bead groups expressed IGF-1 at day 1, 4, and 8.  Results 
indicate that at day 8, the 0 and 5.00 mg/mL HA samples had similar as well as the 
lowest level of IGF-1 expression compared to the 0.05 and 0.50 mg/mL HA groups.  The 
highest level of expression was from the 0.05 mg/mL HA beads, followed by the 0.50 
































Figure 5.6.  All the groups expressed IGF-1R throughout the study.  By day 8, the IGF-
1R expression was lowest for the 0 mg/mL HA group compared to the other samples.  
































Figure 5.7.  IGFBP-3 mRNA expression for all sample groups over 8 days.  A decrease 
in IGFBP-3 expression occurred for all groups by 8 days.  The means and standard 







































Figure 5.8.  Type II collagen mRNA expression was sustained throughout the 8 day 
study for all the sample groups.  However, a decreasing trend occurred by all the groups 
from day 1 to 8.  At day 8, the 0 mg/mL HA case had the lowest type II collagen 
expression compared to the groups that contained hyaluronic acid.  The means and 



































Figure 5.9.  Type I collagen mRNA expression for all sample groups over 8 days.  A 
higher level of expression occurred in the beads that contained hyaluronic acid versus the 
0 mg/mL HA group by the day 8 time point.  The means and standard deviations are 


























































































Figure 5.10.  Immunohistochemistry staining at day 8 for CD44, IGF-1, type II collagen, 
and type I collagen.  The 0, 0.05, 0.50, and 5.00 mg/mL HA groups are all represented 
here, as well as the negative staining control (NTC).  Most of the staining occurred 

































Figure 5.11.  IGF-1 diffusion through 0 mg/mL and 5.00 mg/mL HA alginate hydrogels.  
The 0 mg/mL HA released twice as much IGF-1 compared to the 5.00 mg/mL HA gels.  




6 In Vivo Investigation of IGF-1 Delivery Effects on 
Chondrocytes Embedded in an Alginate/Hyaluronic Acid 
Hydrogel 
6.1 Introduction 
Articular cartilage is a delicate tissue and unfortunately it does not have the 
reparative capacity to heal when it has become damaged or diseased.  The limited ability 
for cartilage to restore itself to a healthy state has led tissue engineers to determine 
innovative methods to aid in cartilage regeneration.  Most of the approaches involve 
utilizing a biomaterial as a drug delivery vehicle for growth factors and/or scaffold for 
chondrocytes or stem cells [3, 287-289].  Therefore, biomaterial interactions are an 
important attribute to understand when creating an engineered cartilage construct. 
Alginate hydrogels are commonly used as a scaffold because it can maintain 
chondrocyte phenotype and viability [103, 106, 116, 132, 230, 250].  The lack of amine 
groups on alginate chains provides a simple environment with minimal interaction to 
embedded chondrocytes [251, 252].  Therefore, allowing researchers to investigate how 
the addition of specific components affects chondrocyte signaling.  For instance, in our 
previous work we introduced insulin-like growth factor-1 (IGF-1) to an alginate hydrogel 
with embedded chondrocytes [272].  By exogenously delivering IGF-1, this resulted in 
down-regulating chondrocytic IGF-1 expression [272].  Interestingly, by incorporating 
hyaluronic acid (HA) into alginate hydrogels an anchoring site for the chondrocytes was 
established that ultimately hindered the diffusion of free IGF-1 (Figure 5.11).  As a result, 
increasing concentrations of HA was able to decrease IGF-1 expression.  From these in 




is known that in vitro and in vivo studies do not always correlate as there are many more 
variables to influence the construct in an in vivo environment.  Therefore, these 
interesting results led us to investigate how HA and IGF-1 would impact chondrocytes 
embedded in alginate hydrogels in an in vivo scenario. 
Previous in vivo work has shown that chondrocytes in alginate hydrogels are 
implantable in animal models and can aid in cartilage growth [291, 292].  Additionally, 
hyaluronic acid hydrogels have also been tested to determine their capacity to grow 
cartilaginous tissue [293-295].  However, a combination of alginate and hyaluronic acid 
hydrogels with IGF-1 delivery as a potential cartilage construct has been minimally 
studied in vivo [296].  The limited knowledge available has led us to investigate how an 
initial batch delivery of IGF-1 affects an in vivo transplanted hydrogel construct that is 
composed of alginate with varied HA concentrations with embedded chondrocytes.  
Therefore, the objectives of this in vivo study were to determine how chondrocytes are 
influenced by HA concentration and IGF-1 delivery by observing cell proliferation as 
well as glycosaminoglycan, IGF-1, type II collagen, and type I collagen protein 
production.. 
6.2 Materials and Methods 
6.2.1 Materials 
The following items were purchased from Invitrogen (Carlsbad, CA): Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12 Ham (DMEM/F12), 
penicillin/streptomycin, fungizone/amphotericin B,  HISTOSTAIN®-SP Kit, and Liquid 
DAB Substrate Kit.  The ascorbic-2-phosphate, bovine serum albumin, sodium 




Streptococcus equi (53747, 1.63 x 106 Da), and sodium cacodylate were purchased from 
Sigma-Aldrich (St. Louis, MO).  ITS+ Universal Culture Supplement Premix was 
purchased from BD Biosciences (San Jose, CA).  Collagenase P was purchased from 
Roche (Basel, Switzerland).  The human insulin-like growth factor-1 (hIGF-1) and anti-
IGF-1 was obtained from R&D Systems (Minneapolis, MN).  The anti-type II collagen 
(ab300), anti-type I collagen (ab6308), and HRP conjugated goat secondary antibody 
(ab6885) were purchased from Abcam (Cambridge, MA).  The Citrisolv Hybrid, Fast 
Green, hematoxylin, and eosin were purchased from Fisher Scientific (Pittsburgh, PA).  
The Safranin-O was obtained from Poly Scientific (Bay Shore, NY).  The 12 mm 
diameter polyester membrane transwell inserts with 3 μm pore size were obtained from 
Corning Incorporation (Corning, NY). 
6.2.2 Methods 
6.2.2.1 Cartilage Extraction and Chondrocyte Isolation 
Slices of cartilage were removed from the metatarsal phalangeal joints of 2-3 
week old calves after 6 hours of slaughter (RanchoVeal, Petaluma, CA).  The pieces were 
rinsed in DMEM/F12 with 50 μg/mL ascorbic-2-phosphate, 1 mg/mL bovine serum 
albumin, 2.6 mg/mL sodium bicarbonate, 2.5 μg/mL fungizone/amphotericin B, and 
0.1% penicillin/streptomycin.  Cartilage was incubated overnight in 0.2% collagenase P 
at 37 oC and then filtered through a 70 µm nylon mesh to isolate primary chondrocytes. 
 
6.2.2.2 Chondrocyte Encapsulation and Culture 
Alginate hydrogels at a 2.0% w/v concentration were made by mixing and heating 




Hyaluronic acid was also added to the alginate solution at three different concentrations 
(0, 0.5, and 5.0 mg/mL).  The final alginate/hyaluronic acid solution was sterilized using 
a 0.22 μm syringe filter and then mixed with chondrocytes at a density of 7,000,000 
cells/mL.  This solution was injected at a volume of 200 μL into transwell inserts.  The 
constructs was placed in 4 mL of 100 mM calcium chloride and then rinsed with 
DMEM/F12 for 30 minutes before being removed from the insert and placed in a 6 well 
plate with DMEM/F12 with 10% heat activated FBS (placed in 57oC for 1 hour).  After 3 
day of culture, all the constructs was placed in DMEM/F12 with ITS+ (1:100 dilution).  




The work described in this study was approved by the University of Maryland 
College Park IACUC (#R-07-93) as well as the University of California Davis Medical 
Center IACUC (#13234).  Male SCID mice (Charles River Laboratories, Wilmington, 
MA) that are 4-6 weeks old were anesthetized using Isoflurane 1-3% and the surgical site 
was shaven with clippers and scrubbed with Betadine solution.  An incision of ~12mm 
was made through the full thickness of the skin on the ventral and dorsal side of the 
mouse.  Two subcutaneous pockets were created by blunt dissection on the ventral and 
dorsal side of the mouse.  The constructs were cut in half and were inserted into the sites 
as semi-circle constructs (4 total samples in each mouse).  The skin was closed by sterile 
surgical clips.  Carprofen was administered at 5 mg/mL S.C. during the procedure to 




anesthesia and returned to the cage.  After 7, 14, and 21 days the mice were euthanized 
by carbon dioxide through inhalation and the constructs were collected for analysis.   
 
6.2.2.4 Histology 
The constructs were physically stable before implantation however they broke 
into smaller pieces upon retrieval.  All samples were fixed in 4% paraformaldehyde and 
0.1 M sodium cacodylate buffer containing 10 mM CaCl2 (pH 7.4) for 24 hours at 4
oC.  
The beads were washed with 0.1 M sodium cacodylate buffer with 10 mM CaCl2 (pH 
7.4) for 24 hours at room temperature.  Afterwards, the beads were dehydrated in a series 
of ethanol concentrations (70-100%) with a final xylene wash.  The samples were 
embedded in paraffin and cut into 6 µm thickness sections, which were placed onto 
charged microscope slides and kept at 4oC until staining. 
 
6.2.2.5 Histochemical Staining 
Sections were oven dried for 2 hours at 60oC, deparaffinized in Citisolv Hybrid 
and then rehydrated in ethanol (100% and 70%), and rinsed in distilled water.  Sections 
were stained with Hematoxylin and Eosin (H&E) and Safranin-O (0.1%) with Fast Green 
(0.001%) counter stain.  All samples were dehydrated, cleared in Citrisolv Hybrid, and 
coverslipped with mounting medium. 
 
6.2.2.6 Immunohistochemistry 
Sections were oven dried, deparaffinized, and rehydrated as described above.  The 
following antibodies were used to stains for the presence of IGF-1, type II collagen, and 




antibody used for IGF-1 was diluted 1:250.  A HISTOSTAIN®-SP Kit and DAB 
Substrate Kit was used to reveal the presence of type II collagen and type I collagen by 
using a hydrogen peroxidase (HRP)-strepavidin-biotin system.  For IGF-1 detection, only 
the Liquid DAB Substrate Kit was used.  All samples were counterstained with 
hematoxylin, dehydrated, cleared in Citrisolv Hybrid, and coverslipped with mounting 
medium.  To show non-specific staining, samples were not incubated with the primary 
antibody and then incubated with the secondary antibody for each protein (negative 
staining control, NTC). 
 
6.2.2.7 Histomorphometrical Analysis 
For all the groups at each timepoint, sixteen randomly chosen Safranin-O/Fast 
Green stained images were captured using a Zeiss Axiovert 40 CFL inverted microscope 
(Carl Zeiss, Oberkochen, Germany).  Chondrocytes were counted on each image and 
reported as cell count per image area.  Additionally, measurements were taken of 
glycosaminoglycan (GAG) production as GAG area minus cell area per image area for 
each slide.  The measurements were calculated using the SPOT Advanced software 
(Diagnostic Instruments Inc., Sterling Heights, MI).  Figures 6.1 is a representative image 
of cell counting and GAG measurements. 
 
6.2.2.8 Statistical Analysis 
Data from all studies were analyzed using ANOVA and Tukey’s multiple-





6.3.1 Cell Morphology, Viability, and Proliferation 
Chondrocyte morphology and viability was observed from H&E stained images.  
For all the groups at each time point, chondrocytes maintained their rounded morphology 
as well as viability (Figure 6.2 is a representative image).  Additionally, all the 
chondrocytes were uniformly distributed throughout the construct.  Chondrocytes were 
counted from Safranin-O/Fast Green stained images (nuclei stained gray) and reported as 
cell count/μm2 x 106 (Figure 6.3).  Initially, the 0.5 mg/mL HA (-) and 5.0 mg/mL HA (-) 
has significantly higher cell counts compared to the rest of the groups (p < 0.05).  By day 
14, most of the samples had an increase in cell number with the highest fold increase of 
~3 by the 0 mg/mL HA (-) and 5.0 mg/mL HA (+) groups from day 7.  As a result these 
groups were found to be significantly higher in cell count from the other cases (p < 0.05).  
The number of chondrocytes decreased by 2 fold for the 0 mg/mL HA (-) and 5.0 mg/mL 
HA (+) groups.  However, the 0.5 mg/mL HA (+) group had a 2.2-fold increase from day 
14 to 21 while all the groups maintained similar cell counts.  Ultimately, the 0 mg/mL 
HA (-) group had the lowest number of chondrocytes and the 0.5 mg/mL HA (+) group 
contained the highest number of chondrocytes by day 21 compared to all the groups (p < 
0.05). 
6.3.2 Glycosaminoglycan Production 
Safranin-O/Fast Green stain turns glycosaminoglycan molecules into a light 
orange hue compared to alginate which becomes a very bright orange color [256].  For 




103 (Figure 6.4).  At day 7, all the groups did not have significantly different GAG areas 
(p < 0.05).  By day 14, most of the samples increased in GAG production.  The 0 mg/mL 
HA (-) and (+) case increased GAG area by 3 and 3.7 fold, respectively.  A 1.7 and 1.8 
fold increase in GAG was observed for the 0.5 mg/mL HA (-) and (+) group.  The 
greatest GAG area was calculated for the 5.0 mg/mL HA (-) and (+) groups at day 14, 
which increased by 4.4 and 5.4 fold.  IGF-1 did not create significant differences ffor the 
5.0 mg/mL HA cases at day 14.  However, the 0, 0.5, and 5.0 mg/mL HA cases were 
significantly different from one another (p < 0.05).  By day 21, the 0 mg/mL HA (-) and 
(+) group as well as the 5.0 mg/mL HA (-) and (+) group maintained similar levels of 
GAG compared to their respective groups at day 14.  An increase in GAG area was 
observed by the 0.5 mg/mL HA group by 1.9 and 2.5 fold for the (-) and (+) samples 
respectively.  Similarly to day 14, IGF-1 did not create differences in GAG area for each 
group but HA concentration created variations in measured GAG area at day 21 (p < 
0.05). 
A ratio of GAG area to cell count was calculated to determine how much GAG 
was produced per chondrocyte in a given area (Figure 6.5).  The results showed that at 
day 7, the 0 mg/mL HA (-) group had the highest ratio compared to the rest of the 
samples (p < 0.05).  By day 14, IGF-1 did not influence the ratios for the 0, 0.5, and 5.0 
mg/mL HA groups.  GAG area/chondrocyte was significantly different amongst the 0, 
0.5, and 5.0 mg/mL HA cases (p < 0.05).  The highest GAG area/cell count ratio was 
calculated for the 5.0 mg/mL HA case (p < 0.05).  At day 21, the 0 mg/mL HA (+) and 
0.5 mg/mL HA (+) group had the lowest ratio compared to all the groups at this time 




cases had similar ratio levels while all the other groups increased by either day 14 or 21.  
The 5.0 mg/mL HA (-) and (+) group had a 2.8 and 2 fold increase respectively from day 
7 to 14 and maintained their ratio from day 14 to 21.  The 0 mg/mL HA (-) and 0.5 
mg/mL HA (-) samples showed ratios that had an increasing trend throughout the study. 
6.3.3 Immunohistochemistry Analysis 
For each group at day 21, representative immunohistochemistry stained images 
for IGF-1, type II collagen, and type I collagen can be seen in Figure 6.6.  The presence 
of each protein is indicated by a brown color as a result of using DAB.  IGF-1 staining 
was observed for all the groups.  Specifically, with or without pre-culture of IGF-1, as the 
HA concentration increased the staining intensity decreased.  When comparing the 0, 0.5, 
and 5.0 mg/mL HA groups individually, IGF-1 staining was less in the samples that were 
delivered with IGF-1 compared to the free IGF-1 samples.  All the samples had a 
significant presence of type II collagen by 21 days and had similar amounts of type II 
collagen.  Type I collagen staining was observed for all the samples as well.  However, 
the staining was less intense in all the groups compared to the type II collagen stained 
images.  The presence of type I collagen seemed to increase with HA concentration for 
the groups that were not cultured with exogenous IGF-1.  An opposing trend is seen for 
the samples that are exposed to excess IGF-1; by increasing HA concentration the type I 
collagen staining intensity decreased. 
6.4 Discussion 
Hyaluronic acid is an extracellular matrix protein that is present in cartilage and 




The ability for hyaluronic acid to interact with various components such as cells and 
proteins makes it an important molecule to investigate.  Our previous work has shown 
that hyaluronic acid in an alginate hydrogel has the ability to retain IGF-1 (Figure 5.11).  
This allows for increased interaction between the exogenous IGF-1 with the embedded 
chondrocytes and was able to down-regulate the endogenous expression of IGF-1.  This 
intriguing in vitro outcome led us to explore how HA and IGF-1 affect chondrocytes 
within a 3-D hydrogel in vivo. 
Chondrocytes maintained their viability indicating that they were stable in the 
hydrogels during the 27 day in vivo experiment (Figure 6.2).  Additionally, throughout 
the study chondrocytes were observed to proliferate modestly (Figure 6.3).  By day 7, the 
0.5 mg/mL HA and 5.0 mg/mL HA groups without IGF-1 had the highest cell counts.  
Indicating that HA has an affect on initial chondrocyte proliferation but its influence on 
the chondrocytes can be diminished by pre-culturing the samples with IGF-1.  By day 14 
most of the samples reached similar cell count numbers except for the 0 mg/mL HA (-) 
and 5.0 mg/mL HA (+) groups which were higher by at least 2-fold.  When observing the 
changes that occurred from day 7 to 21, for most of the samples the cell counts increased 
by a maximum of 2-fold except for the 0.5 mg/mL HA (+) group which had a 4-fold 
increase.  It seems that by day 21, the 0 mg/mL HA (-) group had the lowest cell count 
indicating hyaluronic acid and pre-culturing with IGF-1 has an impact on the overall 
proliferate capacity of chondrocytes in vivo.  Since the highest cell count was observed 
by the 0.5 mg/mL HA (+) group, this possibly suggests that concentration of HA is a 




In regards to glycosaminoglycan production, by day 14 and 21 there are 
considerable differences among the 0, 0.5, and 5.0 mg/mL HA groups with no variations 
between the (-) and (+) cases for each group (Figure 6.4).  These results imply that HA 
has a greater impact than pre-culturing with IGF-1 has a minimal influence on overall 
GAG production.  At the later timepoints the 5.0 mg/mL HA group had the highest GAG 
area.  By day 21, it seems that there is a correlation between GAG area and HA 
concentration as seen by the increasing trend between HA concentration and GAG area.  
Previous works have shown that incorporation of hyaluronic acid in a construct has a 
positive influence on GAG production in vivo [298, 301].  This data further supports that 
HA has the abilty to control the synthesis of GAG. 
When observing the cell count and GAG area for each group, it was interesting to 
see how much GAG area was produced per chondrocyte (Figure 6.5).  At day 21, results 
indicate that for the 0 mg/mL HA and 0.5 mg/mL HA cases pre-culturing IGF-1 affects 
GAG production per chondrocyte.  Additionally, the 0 and 0.5 mg/mL HA (-) cases along 
with the 5.0 mg/mL HA (-) and (+) samples had similar GAG areas.  These observations 
were not noticeable in Figure 6.4.  The result in Figure 6.5 indicates that in 0 mg/mL and 
0.5 mg/mL HA cases, IGF-1 hinders the amount of GAG produced per chondrocyte.  By 
pre-culturing IGF-1 to the alginate/HA constructs, the chondrocytes decreased their total 
GAG production.  Therefore, indicating that exogenous IGF-1 delivery impacts 
chondrocyte GAG activity with low levels of HA in alginate hydrogels.  However, by 
incorporating a high HA concentration of 5.0 mg/mL, IGF-1 delivery did not change 
GAG production per chondrocyte.  This could be due to interactions that occur at high 




synthesis by chondrocytes.  We speculate that at high concentrations of HA leads to 
increased specific (e.g., binding) interactions with IGF-1 or chondrocytes and as a result 
increases GAG production per chondrocyte.  Therefore, we were able to observe similar 
levels of GAG per chondrocyte for the 5.0 mg/mL HA group regardless of IGF-1. 
The initial culturing of the constructs with exogenous IGF-1 led to interesting 
IGF-1 immunohistochemical results (Figure 6.6).  In particular, incorporating more 
hyaluronic acid in the alginate constructs downregulated IGF-1 production.  Furthermore, 
the synthesis of IGF-1 was further diminished in the 0, 0.5, and 5.0 mg/mL HA cases 
with the introduction of exogenous IGF-1.  Indicating that HA and/or pre-culturing with 
IGF-1 decreases endogenous IGF-1 synthesis. 
All the constructs produced type II collagen as seen by the images taken at day 21 
in Figure 6.6, thus showing that the chondrocytes were phenotypically stable throughout 
the study.  Interesting trends were observed for the type I collagen images (Figure 6.6).  
By increasing HA concentration, chondrocytes upregulated type I collagen synthesis 
indicating that hyaluronic acid enables chondrocytes to maintain a fibroblastic phenotype.  
However by pre-incubating the samples with IGF-1, the affects of HA was reversed as 
seen by the decreasing type I collagen staining with increasing HA.  Therefore, indicating 
that exogenous IGF-1 can counteract the negative affect of HA concentration on type I 
collagen synthesis. 
The goal of this study was to show how hyaluronic acid and exogenous delivery 
of IGF-1 were able to influence chondrocytes embedded in alginate hydrogels in vivo.  
Chondrocytes were influenced by HA concentration, specifically without IGF-1 delivery 




HA content increased while IGF-1 staining decreased.  When the constructs were pre-
cultured with IGF-1, total glycosaminoglycan content was not affected, IGF-1 synthesis 
decreased further, and type I collagen staining decreased.  Interestingly, there were no 
trends observed for chondrocyte proliferation or type II collagen staining.  The fact that 
all the samples produced considerable amounts of type II collagen by day 21 suggests 
that the construct properties are beneficial for maintaining chondrocyte function in vivo.  
However, the results specifically observed from this study indicated that the 5.0 mg/mL 
HA (+) case is the best group because of the high production of GAG with minimal type I 
collagen staining.  Overall, this in vivo study clearly shows that HA concentration and 
IGF-1 can modify chondrocyte expression through their interactions. 
6.5 Conclusions 
Hyaluronic acid concentration in an alginate hydrogel can change the production 
of extracellular matrix proteins, such as GAGs and collagens, in an in vivo environment.  
Additionally, pre-culturing constructs with IGF-1 also affects how chondrocytes respond 
to HA in vivo.  In this particular study, delivering exogenous IGF-1 along with increasing 
HA produced the highest GAG amounts while minimizing the production of fibroblastic 
type I collagen protein.  Though the specifics in how HA and IGF-1 interact with one 
another still need to be investigated, the overall results validate the importance of 
balancing components in a construct and understanding how each factor influences one 







Figure 6.1.  A representative image of how the glycosaminoglycan areas were measured 






Figure 6.2.  H&E image from 0 mg/mL HA group with IGF-1 pre-culture at day 21.  
Chondrocytes were evenly distributed in the hydrogel and maintained their viability and 
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Figure 6.3.  Chondrocytes were counted on Safranin-O/Fast Green stained images to 
determine cell proliferation throughout the study.  Cell count per slide area was graphed 
for all the groups at day 7, 14, and 21.  Chondrocytes were able to proliferate in all the 
cases.  However by day 21, the 0.05 mg/mL HA (+) group had the greatest number of 
chondrocytes per area and the 0 mg/mL HA (-) group had the lowest.  The means and 
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Figure 6.4.  Glycosaminoglycan area was measured from Safranin-O/Fast Green stained 
samples.  The total GAG area was calculated per slide area for each case at each 
timepoint.  At day 21, the GAG area increased with higher HA content.  The greatest 
GAG amount was measured in the 5.0 mg/mL HA group.  The means and standard 
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Figure 6.5.  The total GAG area per cell count was calculated for each group at day 7, 
14, and 21.  At day 21, the GAG production per chondrocyte was lowest in the 0 mg/mL 
HA and 0.5 mg/mL HA groups that were pre-cultured with IGF-1 (+).  The means and 
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Figure 6.6.  Immunohistochemical staining of IGF-1, type II collagen, and type I 
collagen for all the groups at day 7, 14, and 21.  The 0, 0.5, and 5.0 mg/mL HA groups 
are all represented here, as well as the negative staining control (NTC).  The scale bars 





The poor intrinsic ability for articular cartilage to repair itself after becoming 
diseased or damaged has resulted in applying tissue engineering applications to aid in 
healing.  In order to create a proper construct, chondrocyte signaling within a biomaterial 
needs to be fully understood.  In this particular work, the overall goal was to investigate 
how construct properties alter IGF-1 signaling by chondrocytes in vitro and in vivo. 
The first objective was to vary alginate concentration, which alters the water 
content of the hydrogel.  Additionally, the paracrine signaling distance was modified by 
changing the density of chondrocytes embedded in each alginate hydrogel bead. We 
investigated the effects of these fabrication parameters, alginate concentration and cell 
density, on chondrocyte IGF-1 expression and phenotypic type II collagen expression 
over 8 days using quantitative reverse-transcriptase polymerase chain reaction (qRT-
PCR).  IGF-1 expression was greater for the 100,000 versus 25,000 cell density case, 
therefore showing the impact of paracrine signaling distance.  At the 100,000 cell density 
case, IGF-1 expression was significantly altered by alginate concentration with the 
highest expression occurring in 2.0% w/v alginate.  Type II collagen expression was 
observed to be the highest in the 100,000 cell density and 2.0% w/v alginate case.  The 
results suggest that high cell density at high alginate concentration can significantly affect 
the endogenous IGF-1 expression as well as type II collagen expression by chondrocytes.  
From these findings, the 2.0% w/v alginate with 100,000 chondrocytes per bead was used 
as a basis for the other objectives. 
The second objective was to examine the effects of IGF-1 delivery to 




upstream IGF-1 signaling molecules: IGF-1, IGF-1R, and IGFBP-3.  The lack of amine 
groups on alginate hydrogels allows us to clearly investigate solely on how exogenous 
IGF-1 affects chondrocyte signaling.  Three different IGF-1 concentrations were 
incubated with the chondrocytes: 0, 10, 50, and 100 ng/mL.  IGF-1 delivery to the 
construct led to an increase in glycosaminoglycan as well as type II collagen production 
by 8 days.  Additionally, type II collagen expression was the highest along with type I 
collagen expression being the lowest for chondrocytes exposed to IGF-1.  IGF-1 
expression was higher for chondrocytes incubated without IGF-1 compared to the IGF-1 
delivered groups.  This result was expected as chondrocytes are attempting to overcome 
the lack of IGF-1 signal by increasing their endogenous expression of IGF-1.  The 
presence of IGF-1 led chondrocytes to express higher levels of IGF-1R, or alternatively a 
greater turnover rate of IGF-1R so as to potentially bind more available IGF-1.  IGFBP-3 
did not appear to be largely influenced by IGF-1 delivery with an observed decrease in 
expression.  Therefore, indicating that IGF-1R is a key factor in regulating IGF-1 
signaling.  These results confirm the significant role of IGF-1 in chondrocyte function as 
endogenous expression.  Interestingly, similar expression levels and protein production 
occurred for all the IGF-1 concentrations.  Therefore, the highest IGF-1 concentration at 
100 ng/mL was utilized in the following experiments. 
The third objective was to investigate how an extracellular matrix protein alters 
IGF-1 signaling of chondrocytes embedded in an alginate hydrogel.  Hyaluronic acid is a 
large glycosaminoglycan present in cartilage.  Chondroctyes adhere to this molecule 
through the receptor CD44.  In this particular study, varying concentrations of hyaluronic 




previously determined the effects of IGF-1 delivery on chondrocyte signaling.  Therefore, 
we investigated how hyaluronic acid affects IGF-1 delivery on chondrocyte IGF-1 
signaling.  IGF-1 expression was highest for alginate containing 0.50 mg/mL hyaluronic 
acid while the lowest was observed for the 0 mg/mL and 5.00 mg/mL hyaluronic acid 
cases.  It seems that at low hyaluronic acid concentrations, hyaluronic acid interaction 
with chondrocytes results in higher endogenous IGF-1 expression.  However at a high 
concentration of hyaluronic acid the retention of free IGF-1 molecules in alginate 
hydrogels was significant, which allowed for continuous interaction of IGF-1 to the 
chondrocytes. These results indicate that hyaluronic acid can vary the expression levels 
of IGF-1.  Additionally, the expression of IGF-1R was also influenced by hyaluronic acid 
because unlike the previous study, IGF-1 and IGF-1R did not correlate in expression.  
IGFBP-3 expression was minimally affected by hyaluronic acid.  Hyaluronic acid did not 
signfignicantly alter type II collagen expression.  However, hyaluronic acid increased 
chondrocyte expression of type I collagen.  The results show that incorporation of 
hyaluronic acid can affect how exogenous IGF-1 interacts with embedded chondrocytes 
in alginate hydrogel.  These in vitro results were intriguing and therefore led us to 
investigate our model in vivo. 
Finally, the fourth objective was to determine how chondrocytes are influenced by 
construct properties in vivo.  Chondrocytes were embedded in 2.0% w/v alginate 
hydrogels with varying hyaluronic acid concentrations (0, 0.5, and 5.0 mg/mL).  These 
constructs were delivered with or without IGF-1 (1 g/mL) and then subcutaneously 
implanted in SCID mice.  IGF-1 pre-culture was found to have a strong impact on how 




cases but little influence on the 5.0 mg/mL group by day 21.  By incorporating more 
hyaluronic acid in the alginate constructs resulted in downregulation of IGF-1 production.  
Furthermore, the synthesis of IGF-1 was further diminished in the 0 and 0.5, and 5.0 
mg/mL HA cases with the introduction of exogenous IGF-1.  Therefore, indicating that 
pre-culturing with IGF-1 has a significant influence on endogenous IGF-1 synthesis.  
Chondrocytes were phenotypically stable in the all the constructs during the in vivo study.  
A decrease in type I collagen occurred as hyaluronic acid concentration increased.  
However by pre-incubating the samples with IGF-1, the affects of hyaluronic acid was 
reversed.  Therefore, showing that exogenous IGF-1 can counteract the affect of HA 
concentration on type I collagen synthesis.  These results indicate that the ideal construct 
would be 5.0 mg/mL hyaluronic acid with IGF-1 because of the high amounts of 
glycosmaminoglycan production with minimal type I collagen staining.  This in vivo 
study clearly shows that HA concentration and IGF-1 content are able to counter act each 
other. 
This work shows how construct properties are able to influence chondrocyte 
expression of upstream IGF-1 signaling molecules by observing how alginate 
concentration, cell density, exogenous IGF-1 delivery, and hyaluronic acid concentration 
affect endogenous IGF-1 signaling both in vitro and in vivo.  Overall, in order to properly 
engineer articular cartilage it is important to create a balance in construct components by 
understanding how various factors influence one another. 
8 Conclusions 
Articular cartilage does not have an innate ability to repair.  Unfortunately, as a 




widely used medical approach currently for small lesions is Carticel® which implants 
autologous chondrocytes into the defect site.  Another product is NeoCart®, which is in a 
clinical trial phase, which utilizes autologous chondrocytes with a scaffold for 
implantation.  These products have shown promise to minimize pain to patients and allow 
them to be more physically active.  However, their long term affects are unclear and their 
ability to actually completely heal cartilage is unknown.  For these reasons, engineering 
articular cartilage is still of relative importance and therefore research is still being 
continuously conducted.  In order to achieve the ultimate goal of creating a construct that 
will be able to form into cartilage, the details of the construct must be fully understood.  
Therefore, in this work we investigated how various molecules influence chondrocyte 
expression, specifically upstream IGF-1 signaling molecules, type II collagen, and type I 
collagen.  From the results found, it is clear that by just adding one element into a 
construct, there was significant variance in mRNA and protein expression levels of IGF-
1, IGF-1R, type II collagen, and type I collagen.  Overall, this work depicts the 
importance of studying how embedded chondrocytes in 3-D microenvironments express 
signaling molecules.  We hope that future works will investigate how construct properties 




9 Future Works 
The work that has been completed thus far opens up a numerous number of 
possible future studies.  The intricate detail of IGF-1 signaling by chondrocytes is still 
under investigation and it is of great interest to tissue engineers.  In this particular work 
we focused on how the expression of upstream IGF-1 signaling molecules changed by 
only altering a few construct properties.  Therefore, a future goal of this project could be 
to determine how the constructs can be modified further to enhance chondrocyte IGF-1 
signaling. 
Perhaps first investigate the intracellular pathways, MAPK, PI3K, p38, and JNK, 
for IGF-1 more closely as well as type II collagen signaling.  This can provide more 
details of how endogenous IGF-1 and type II collagen signaling are correlated with each 
other.  Additionally, how construct properties specifically change IGF-1 signaling. 
Another goal would be to utilize mesenchymal stem cells (MSCs).  There is a 
tremendous amount of interest in MSCs for cartilage repair because of its ability to 
differentiate into chondrocytes as well as being highly proliferative, which does not seem 
to occur by chondrocytes.  It would be interesting to determine how IGF-1 affects MSCs 
to differentiate into chondrocytes.  Chondrocytes can be transfected with DNA plasmid 
that induces higher IGF-1 protein production.  These chondrocytes can then be incubated 
with MSCs and IGF-1 signaling can be monitored at the gene and protein level by both 
cell types.  By placing these cells in a construct, the biomaterial properties can be 
changed to determine how to enhance MSCs to differentiate (e.g., express type II 




While the overall goal is to create a tissue engineering construct that will be able 
to regenerate articular cartilage, we believe that it is very important to study the basic 
details of cell signaling.  Therefore, our current future goals are focused on how to 
enhance IGF-1 and type II collagen signaling in chondrocytes or MSCs so that a better 
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11 Appendix A: Cell-to-Cell Distance Calculation 
Variables: 
x = # of chondrocytes per alginate bead 
RA = radius of alginate bead = 1500 m 
RC = radius of chondrocyte = 7.5m 





















































Cell to Cell Distance =  CV RR 2  
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